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ABSTRACT OF DISSERTATION 
 
 
 
 
RENAL HUMORAL, GENETIC AND GENOMIC MECHANISMS UNDERLYING 
HERTIABLE HYPERTENSION 
 
 
In spite of significant progress in our knowledge of mechanisms that control 
blood pressure, our understanding of the pathogenesis of hypertension, its 
genetics, and population efforts to control blood pressure, hypertension remains 
the leading risk factor for mortality worldwide.  It’s estimated that 1 out of every 3 
adults has hypertension.  Hypertension is a major risk factor for cardiovascular 
disease and stroke, and is considered a primary or contributing cause of death to 
more than 2.4 million US deaths each year.   Although spontaneous hypertension 
has been the subject of substantial research, many critical questions remain 
unanswered.   
 
To investigate mechanisms underlying spontaneous hypertension, a unique 
rodent breeding approach was used to isolate nuclear and mitochondrial genes 
contributing to the disease.  By diluting the nuclear genome of the Spontaneously 
Hypertensive Rat on a normotensive Brown Norway background while 
maintaining the SHR mitochondrial genome, I investigated both intrinsic and 
extrinsic mechanisms of the kidney and its relationship to hypertension.  Chapter 
2 documents the dominance of the hypertensive phenotype in our rodent colony, 
despite the dilution of the nuclear genome of the SHR.  Chapter 3 presents data 
indicating that the renin-angiotensin system, particularly the location and 
abundance of the AT1 receptor may play an important role in the manifestation of 
spontaneous hypertension.   Chapter 4 presents that rats in our rodent colony 
exhibited normal pressure-natriuresis and kidney function; however, hypertensive 
rats had a reduced ability to sense orally ingested sodium chloride, thus 
necessitating chronic elevations of arterial pressure in order to maintain sodium 
balance.  This chronic pressure-natriuresis relationship shifts the renal function 
curve to the right, thus sustaining elevated blood pressure.  Chapter 5 presents 
data that genes important for oxidative phosphorylation may play a critical role in 
the development of hypertension.  Both nuclear and mitochondrial oxidative 
 
 
phosphorylation genes were downregulated in hypertensive rats compared with 
normotensive rats.  Data presented in every chapter highlights the importance of 
the kidney in the pathogenesis of hypertension.  Humoral, genetic and genomic 
mechanisms of the kidney appear to play a dominant role in the development 
and maintenance of the disease.   
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CHAPTER 1 
KIDNEY, LONG-TERM CONTROL OF ARTERIAL PRESSURE AND 
HYPERTENSION 
 
Jason Andrieu Collett 
 
Abbreviations used: BP, blood pressure; TPR, total peripheral resistance; CO, 
cardiac output; RAS, Renin-Angiotensin System, ECFV, extracellular fluid 
volume; AVP, arginine vasopressin;  MD, macula densa’ cTAL, cortical thick 
ascending limb; JGA, juxtaglomerular apparatus; GFR, glomerular filtration rate; 
Ang II, angiotensin II; RPP, renal perfusion pressure; RVLM, rostral ventrolateral 
medulla; NTS, nucleus of the solitary tract; RSNA, renal sympathetic nerve 
activity; RBF, renal blood flow; SNA, sympathetic nerve activity; Ang, 
angiotensin; ACE, angiotensin-converting enzyme; AT1(r), angiotensin II type 1 
receptor; AT2(r), angiotensin II type 2 receptor; CVLM, caudal ventrolateral 
medulla; ENaC, epithelial sodium channel; SFO, subfornical organ; OVLT, 
organum vasculosum of the lamina terminalis; MnPO, median preoptic nucleus; 
PVN, paraventricular nucleus of the hypothalamus; ADH, antidiuretic hormone; 
CVO, circumventricular organs; SON, supraoptic nucleus of the hypothalamus; 
ICV, intraerebroentricular; AP, area postrema; VSMC, vascular smooth muscle 
cells; CNS, central nervous system; ARB, angiotensin II receptor blocker; SHR, 
Spontaneously Hypertensive Rat; IV, intravenously; QTL, quantitative trait loci; 
CNV, copy number variant; OXPHOS, oxidative phosphorylation system; ROS, 
reactive oxygen species; nDNA, nuclear DNA; mtDNA, mitochondrial DNA; 
rRNA, ribosomal RNA; tRNA, transfer RNA; SNPs, single nucleotide 
polymorphisms; ETC, electron transport chain; HNF-1α, hepatocyte nuclear 
factor-1alpha; PGC-1α, Peroxisome proliferator-activated receptor gamma 
coactivator 1 alpha; NRF, nuclear respiration factor(s); Tfam, transcription factor 
A mitochondria; NO, nitric oxide; SOD, superoxide dismutase; NT, normotensive; 
HT, hypertensive;  
 
 
Keywords: Spontaneous hypertension, Renin-Angiotensin System, genomics, 
mitochondria, sympathetic nerve activity, kidney 
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1.1 Introduction 
 
Hypertension and the chronic elevation of blood pressure (BP) constitute a 
primary and significant factor in the development of cardiovascular disease.  
Despite major gains in the long-term treatment of hypertension, cardiovascular 
disease remains the number one cause of death and disability in developed 
countries.  For well over 50 years, scientists have uncovered several 
mechanisms believed to govern the long and short-term control of arterial 
pressure, with much debate on one major governing factor (Cowley 1992).   
Spontaneous hypertension, commonly referred to as essential or primary 
hypertension, is a rise in blood pressure of little known cause.  Spontaneous 
hypertension is a multifactorial disease which accounts for 95% of all cases of 
hypertension in humans.  There is a significant positive and continuous 
relationship between elevated BP and cardiovascular disease (stroke, heart 
failure, myocardial infarction), often resulting in renal disease and even death 
(Carretero and Oparil 2000).  Data from the National Health and Nutrition 
Examination Survey NHANES have indicated that 50 million or more Americans 
have high BP  warranting some form of treatment (Burt, Whelton et al. 1995).  
Worldwide prevalence estimates for hypertension may be as much as 1 billion 
individuals, and approximately 7.1 million deaths per year may be attributable to 
hypertension (Burt, Whelton et al. 1995).   
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Understanding the mechanisms for the long-term control of BP has important 
clinical significance.  Because movement-to-movement and long-term stability of 
arterial pressure is necessary for survival, mammals have evolved many 
redundant controllers that participate in both of these functions.  It is thought that 
the feedback control systems that provide rapid stabilization of arterial pressure 
are fundamentally different than those that determine the long-term level of 
arterial pressure.  Blood pressure, simply defined, is the pressure exerted upon 
the walls of blood vessels.  Figure 1.1 represents the mathematic representation 
(Ohm’s law) of blood pressure (BP=total peripheral resistance (TPR) X cardiac 
output (CO).  Arterial pressure is the consequence of several factors that can 
influence cardiovascular function including both renal intrinsic mechanisms as 
well as extrinsic mechanisms, such as the Renin-Angiotensin System (RAS) and 
the sympathetic nervous system. 
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1.2 The Kidney, Long-term Control of Blood Pressure and Hypertension 
 
It has been hypothesized that the “set point” for the long-term control of BP 
resides in the kidney (Guyton and Coleman 1968; Guyton, Coleman et al. 1972; 
GUYTON, COLEMAN et al. 1974).  In this model, the set-point of the chronic 
renal function curve (Figure 1.2) establishes the steady state relationship 
between renal perfusion pressure and urinary excretion of sodium and water, 
which in turn affects blood volume and CO (Figure 1.1).  This renal-body fluid-
pressure control system exhibits “infinite feedback gain”, i.e., BP will stabilize 
only when intake and output of sodium and water become exactly equal, which 
occurs at one pressure level for any given renal function curve and salt intake 
level (Guyton 1990).  The renal-BP set-point theory predicts that the kidney 
controls BP to maintain its own excretory function and that long-term regulation 
of blood volume and CO are paramount to the regulation of BP.   
 
The mechanism for pressure natriuresis and diuresis, developed in a theoretical 
analysis by Guyton and Coleman, provides the kidney with the long-term ability 
to detect and control arterial pressure (Guyton and Coleman 1968; Guyton, 
Coleman et al. 1972; GUYTON, COLEMAN et al. 1974).  These seminal works 
demonstrated that the mechanism of pressure natriuresis and diuresis is capable 
of determining the long-term level of arterial pressure.  Because the gain for the 
pressure-natriuresis relationship overrides all other regulatory systems in blood 
pressure control, the ultimate determinant of BP must be renal handling of 
sodium (Adamczak, Zeier et al. 2002). 
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The kidney exerts its powerful diuresis- natriuresis mechanism by both sensing 
total extracellular fluid volume (ECFV) and responding to renal perfusion 
pressure (Cowley 1992) (Figure 1.3).  The quantity of NaCl in the extracellular 
fluid compartment and the body’s efficient osmoregulatory system determine total 
ECFV.  The regulation of ECF osmolality by both the kidney and the brain, and 
the rate of fluid entering and exiting the body are important determinants in blood 
pressure regulation.  Osmoreceptors in the brain detect subtle changes in ECF 
sodium concentration and modify thirst and arginine vasopressin (AVP) release 
for restoration, conservation or contraction of body water (Andersson, Dallman et 
al. 1969; Vereerstraeten and Toussaint 1969). The mechanisms controlling 
sodium excretion also contribute importantly to the process of osmoregulation.  
The delivery of filtered sodium to the specialized cells of the renal macula densa 
(MD) is a major effector sensor for sodium loss in the body.  MD cells in the 
cortical thick ascending limb (cTAL) are the sensory element of the 
juxtaglomerular apparatus (JGA) and play an important role in the control of renal 
blood flow, glomerular filtration rate (GFR) and renin release by tubuloglomerular 
feedback (TGF), among other things (Sipos, Vargas et al. 2010).  It has been 
postulated that the MD cells sense Na+, Cl-, or a combination of both, however; 
Sipos et al.  (2010) demonstrated that the macula densa cells of the thick 
ascending limb are equipped with tubular-flow sensing mechanisms that 
contribute to MD cell function, renin release and TGF.   With increased plasma 
sodium filtered at the glomerulus, and more sodium (or chloride or flow) to the 
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MD, renin secretion from JGA is reduced.  Circulating levels of Angiotensin II 
(Ang II) and aldosterone are therefore reduced.  Because Ang II and aldosterone 
are intimately involved in increased sodium reabsorption, and therefore 
determine the rate of sodium loss, it is evident that these and other neural and 
endocrine pathways influence osmoregulation via changes in sodium excretion.   
 
This influential model developed by Guyton postulates that the relationship 
between renal sodium excretion and BP defines the BP homeostatic set-point.   
According to this model, any increase in sodium retention produces an initial 
blood volume expansion causing BP to increase via a rise in cardiac output, as 
illustrated in Figure 1.3.  Eventually, tissue over-perfusion leads to an increase in 
peripheral resistance (whole-body autoregulation) that returns resting cardiac 
output towards normal.  According to this widely held theory, a resetting of the 
pressure–natriuresis relationship inevitably leads to hypertension regardless of 
the cause of the resetting, whether it be humoral, neural, degenerative or genetic 
(Guyton and Coleman 1968). 
 
Renal perfusion pressure (RPP), a direct indicator of arterial pressure, can exert 
a powerful influence on the rate of urine excretion as evidenced by the 
mechanisms mentioned above (Roman and Cowley 1985; Roman, Cowley et al. 
1988).  This response can be, and is, blunted by extrinsic factors such as neural 
and circulation hormones.  However, experiments by Roman et al. showed when 
maintaining neural and circulating hormones at constant levels, small elevations 
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in RPP by abdominal aortic clamping resulted in large increases of urine output 
(Roman and Cowley 1985) .  The reflex neural and endocrine systems that effect 
the pressure-natriuresis relationship, and hence regulation of body volumes must 
be taken into account with understanding long-term BP control.  For instance, the 
diuretic and natriuretic responses observed from carotid-occlusion or epinephrine 
infusion-mediated rises in BP are severely blunted compared to those observed 
using aortic clamps (Kirchheim, Ehmke et al. 1987; Sipos, Vargas et al. 2010).  
These extrinsic mechanisms include, but are not limited to Ang II, 
catecholamines (and renal sympathetic nerve activity), prostaglandins, renal 
kinins, atrial natriuetic factor, vasopressin and endothelin (Cowley 1992). 
 
1.2.1 Sympathetic Nervous System and Blood Pressure Control 
 
There has been much controversy over the pressure-natriuresis theory of the 
main controller of BP, as it states that it is not determined by the generalized 
level of vascular resistance of the systemic circulation (TPR).  Total peripheral 
resistance is defined simply as the sum of the resistance of all peripheral 
vasculature in systemic circulation.  As shown in Figure 1.1, a major contributor 
to TRP is arteriolar smooth muscle contraction via the autonomic nervous 
system.  The neural control of circulation operates via parasympathetic neurons 
that innervate the heart and three main classes of sympathetic efferents; 
barosensitive, thermosensitive and glucosensitive that innervate blood vessels, 
the heart, kidneys and adrenal medulla (Guyenet 2006). The barosensitive 
sympathetic efferents are under the control of arterial baroreceptors.  This large 
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group of efferents has a dominant role in both short-term and potentially long-
term BP regulation (Osborn 2005; Guyenet 2006).  Their level of activity at rest is 
postulated to be an important parameter for long-term BP control. This 
background activity is set by a core network of neurons that reside in the rostral 
ventrolateral medulla (RVLM), the spinal cord, the hypothalamus and the nucleus 
of the solitary tract (NTS). Both variables of BP, TPR and CO are controlled by 
some extent by the autonomic nervous system.   CO is dependent on three 
regulated variables: ventricular end-diastolic volume; myocardial contractility; and 
heart rate. End-diastolic volume is the volume reached by the ventricular 
chamber before contraction and is determined by venous pressure, which is 
related to blood volume and venous smooth muscle tone, both of which are 
under sympathetic control (Osborn 2005).   Myocardial contractility and heart rate 
are regulated by both the sympathetic and parasympathetic divisions of the 
autonomic nervous system.  The autonomic nervous system is able to incur rapid 
changes via CO and regional arteriolar resistance, which can be associated with 
substantial increases in BP.  Significant evidence has implicated the autonomic 
nervous system and the brain in producing long-term changes in BP (Osborn, 
Holdaas et al. 1983; Osborn, Plato et al. 1997; Madden and Sved 2003; Osborn 
2005; Littlejohn, Siel et al. 2013).  Additionally, peripheral efferents have shown 
the same effect.  For instance, increased renal sympathetic nerve activity 
(RSNA) results in increased renin secretion rate, increased renal tubular sodium 
reabsorption and retention, and decreased GFR and renal blood flow (RBF) with 
increased renal vascular resistance (DiBona and Kopp 1997; Osborn, Plato et al. 
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1997; DiBona 2000). Thus, increased RSNA represents an important candidate 
as a mediator of the normal and abnormal renal function and therefore, the 
development of hypertension.  Many reports have implicated neurally-mediated 
mechanisms in the development of hypertension in several animal models (Judy, 
Watanabe et al. 1976; Osborn, Holdaas et al. 1983; Ichihara, Inscho et al. 1997).  
Furthermore, removal of renal nerves completely prevented or delayed the onset 
of hypertension in numerous animal models of hypertension including humans 
with drug-treatment-resistant, primary hypertension (DiBona and Esler 2010).  
Elevated SNA is present in most forms of human hypertension (Wyss 1993)  and 
a causal relationship is suggested by the well-documented antihypertensive 
efficacy of sympatholytic drugs (for example, alpha1- or beta-adrenergic receptor 
antagonists) (James, Oparil et al. 2014).  The sympathetic efferents that 
innervate the kidneys are commonly presented as the only ones that are capable 
of influencing the 24-h average BP (Cowley 1992).  If this theory is correct, a 
more complete knowledge of the neural pathways that selectively regulate renal 
SNA could be key to understanding the contribution of the CNS to hypertension.  
However, elevated RSNA is probably not the sole mechanism involved in 
neurogenic hypertension, and the method by which an increase in SNA raises 
the 24-h mean BP has not been established. The most commonly invoked 
mechanism is resetting of the renal BP–natriuresis relationship to higher levels of 
BP by either a rise in sympathetic tone to the kidney or by hormones whose 
production is partly controlled by the autonomic nervous system (for example, 
Ang II) (Guyenet 2006).  
 
 
10 
 
1.1.2 The Kidney and its Role in Hypertension 
 
The theoretical basis for the role of the kidney in hypertension is well established 
and alterations in kidney function have been identified in the established stage of 
every form of hypertension yet studied (Cowley and Roman 1983).  
Hypertension, therefore, can develop only when something impairs the ability of 
the kidney to excrete sodium and water and shifts the relationship between 
sodium excretion and arterial pressure towards higher pressures.  Renal humoral 
mechanisms and transcriptomics related to the development and maintenance of 
hypertension will be presented in this doctoral thesis, highlighting the importance 
of the kidney in blood pressure control and pathogenesis of the disease. 
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Figure 1.1: Comprehensive contributions to control of BP.  
Mathematically, BP control is equivalent to Ohm’s law, where BP 
is the product of flow (CO) and resistance (TPR).  Additionally, 
CO is the product of HR and SV.  Several factors can directly 
influence these cardiovascular parameters, ultimately influencing 
to BP.  BP=blood pressure, CO=cardiac output, TPR=total 
peripheral resistance, SV=stroke volume, HR=heart rate 
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Figure 1.2: The Renal Function Cure.  Systolic arterial pressure is a 
direct function of urine output (UNaV), and hence kidney function.  This 
relationship exhibits “infinite gain”, i.e., BP will stabilize when intake and 
output of sodium are equal, which occurs at one pressure level for any 
given renal function curve and salt intake.  It is hypothesized that the 
manifestation of hypertension occurs only when a rightward shift in the 
renal function curve occurs, requiring a higher pressure to excrete the 
same level of salt.  A rise BP is “essential” to maintain sodium balance. 
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Figure 1.3: Basic renal-body fluid feedback mechanism for the long-term 
regulation of blood pressure and body fluid volumes.  The kidney, it is 
hypothesized, contains the long-term homeostatic set-point. 
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1.3 Systemic Renin Angiotensin System (RAS): Overview of Components, 
Features and Actions   
 
The RAS is an essential regulator of blood pressure, fluid balance, and 
cardiovascular function. The RAS produces a family of bioactive angiotensin 
(Ang) peptides with a variety of biological and neurobiological activities, with the 
most notable peptide being Ang II.  The components of the RAS are present in 
peripheral tissues such as the vasculature, kidney, brain and heart, all of which 
locally produce Ang II (Peach 1977).   The canonical systemic cascade begins 
with the release of the aspartyl protease renin from the JG cells of the kidneys 
leading to the conversion of circulating angiotensinogen from the liver to inactive 
angiotensin-I (Ang I) which, in turn, is converted to three different peptides; Ang II 
by the dipeptyl carboxypeptidase angiotensin-converting enzyme (ACE) located 
ubiquitously along vascular walls and secreted into the lungs and kidneys, Ang-
(1-7) by neprilysin and Ang-(1-9) by the zinc metalloprotease ACE2 (Figure 1.4).  
Ang-(1-9) is metabolized by the metalloendopeptidase neprilysin to form Ang-(1-
7), which is hydrolyzed by ACE to form Ang-(1-5). Ang II is degraded into the 
smaller, active peptides Ang III, Ang IV and Ang (1-7) by aminopeptidase A, 
aminopeptidase N and ACE2, respectively. Ang II is also converted to Ang-(1-4) 
by neprilysin (Lavoie and Sigmund 2003).  
 
Ang II primarily binds two G-protein coupled receptors, Ang II type 1 (AT
1
) and 
Ang II type 2 (AT
2
) receptor, to produce both harmful and physiological effects on 
cardiovascular health (de Gasparo, Catt et al. 2000; Lavoie and Sigmund 2003). 
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Most of the classical actions of Ang II such as vasoconstriction, sodium retention, 
aldosterone release and sympathetic activation are facilitated by the AT
1 
receptor. There are two AT
1 
receptor isoforms in rodents, AT
1A 
and AT
1B
, and 
only one in humans (de Gasparo, Catt et al. 2000).  Activation of the AT2 
receptor generally has effects that are contrary to AT1 receptor actions-mainly 
vasodilation, natriuresis and antiproliferation (Bottari, de Gasparo et al. 1993).  In 
humans, the AT1 receptor is located in blood vessels, heart, kidney, adrenal 
glands and liver while the AT2 receptor is mainly expressed in fetal tissue, with 
relatively low amounts present in adult tissue (Matsubara 1998). Ang-(1-7), 
acting through the G-protein Mas receptor, has actions that are contrary to the 
effects of Ang II, such as vasodilation, natriuresis and antiproliferation(Santos, 
Simoes e Silva et al. 2003). Ang III (Ang 2-8) is thought to exert its actions at the 
AT1 receptor and may be responsible for effects associated with Ang II, 
especially in the brain (Wright, Bechtholt et al. 1996). Ang IV binds the AT1 and 
AT
 2 
receptors with low affinity and binds its own AT4 receptor. 
 
The RAS has generally been classically affiliated with blood pressure control and 
salt and water balance. Nevertheless, the RAS is continually emerging as a 
complex system involved in many physiological and pathophysiological 
conditions outside of the classic hemodynamic and osmoregulatory effects. The 
RAS contributes to oxidative damage (Sachse and Wolf 2007), insulin resistance 
(Henriksen 2007) and cell-growth (Pawlikowski, Melen-Mucha et al. 1999) and 
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has been implicated in the pathogenesis of the metabolic syndrome, diabetes, 
renal damage and hypertension.  
 
1.3.1Cardiovascular Regulation  
 
The body has several mechanisms to control blood pressure. These 
mechanisms, such as the actions of the RAS, can alter cardiac output, the blood 
volume in the bloodstream and vasoactivity of the arteries. The RAS has 
profound influence on cardiovascular and renal function due to its various actions 
throughout the body.   Ang II is a potent vasoconstrictor, constricting arteries and 
veins to increase blood pressure. Ang II is also involved in fluid reabsorption.  
 
Blood pressure regulation is a separate but not mutually exclusive process: both 
quick BP adjustments via baroreflexes and through long-term control involving 
the kidneys. The baroreflexes are mediated by the sympathetic and 
parasympathetic nervous systems.   The baroreflex, which is a negative-
feedback system, augments blood pressure in a matter of seconds to minutes. 
When blood pressure rises, the carotid and aortic sinuses distend resulting in 
activation of the baroreflex which adjusts sympathetic and parasympathetic 
activity accordingly. Afferent baroreceptor input suppresses sympathetic activity 
through a multisynaptic pathway which starts with excitatory fibers synapsing at 
the NTS. The NTS then sends excitatory (glutamatergic) projections to the 
caudal ventrolateral medulla (CVLM) and nucleus ambiguous (NA).  The 
activated CVLM sends inhibitory (GABAergic) fibers to the RVLM, which then 
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decreases sympathetic nerve activity to the heart and vasculature.   Activation of 
the NA will decrease heart rate by increasing parasympathetic nerve activity to 
the heart via the vagus nerve. The blood pressure is reset back to its original 
point.   The RAS interacts with both these systems to help maintain and regulate 
cardiovascular function.  Ang II modulates baroreflex function by decreasing the 
sensitivity of the gain of the baroreflex (Brooks 1995).  Ang II acts at AT
1 
receptors in the NTS to decrease the baroreflex sensitivity (Diz, Jessup et al. 
2002), whereas Ang-(1-7) enhances the baroreflex sensitivity also by acting at 
the NTS (Ferrario, Chappell et al. 1997). 
 
The kidney is involved in more long-term regulation of blood pressure and the 
RAS has both direct and indirect effects on the kidney.  The RAS partners with 
the kidney to control blood pressure by maintaining salt and water balance. Ang 
II does this through its direct and indirect effects on water and salt reabsorption, 
which leads to an increase in blood pressure. Under physiological conditions, the 
RAS ensures that blood pressure does not drop too low and to maintain proper 
perfusion and blood flow to tissues and organs that need it the most under these 
circumstances. However, chronic activation of Ang II may lead to hypertension 
and damage the various organs and tissues of the body (Lavoie and Sigmund 
2003).  Ang II has a direct effect on the proximal tubules to increase salt 
reabsorption. Indirectly, Ang II causes the adrenal cortex to secrete the 
mineralcorticoid aldosterone which acts on the distal tubules and collecting ducts 
to cause conservation of sodium, water retention and potassium secretion.  The 
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effects that Ang II has on renal blood flow and GFR vary depending on the 
situation.  Ang II constricts the afferent and efferent arterioles and incites 
contraction of the mesangium, resulting in a decrease in renal blood flow, 
glomerular filtration rate and filtered sodium load (Brewster and Perazella 2004).  
Ang II decreases the surface area for glomerular filtration by constricting the 
mesangial cells. The effect on the efferent arteriole is greater in part due to its 
smaller basal diameter.  Efferent arteriole constriction decreases renal blood flow 
and increases glomerular filtration by increasing glomerular capillary pressure.  
This increase in filtration fraction causes an increase in the peritubular vessel 
oncotic pressure and a decrease in the hydrostatic pressure, which also occurs 
in the renal interstitium.  This pressure gradient allows sodium and water to move 
from the proximal tubule to the interstitium.  Ang II decreases medullary blood 
flow and reduces renal interstitial pressure which decreases water and sodium 
excretion (Brewster and Perazella 2004).  Ang II inhibits pressure-natriuresis and 
it is thought to be a TGF modulator because it augments TGF sensitivity (Vallon 
2003). Furthermore, Ang II is involved in the proliferation of nephron cells 
(Zhang, Guo et al. 2004).  
 
Ang II exerts influence on distinct ion channels along the nephron as well.  Ang II 
enhances the sodium/hydrogen (Na
+
/H
+
) ion anti-porter activity on the luminal 
membrane of proximal tubules (Brewster and Perazella 2004) and in the early 
and late distal segments (Wang and Giebisch 1996). The action of Ang II to 
augment distal tubule sodium reabsorption complements the effect in proximal 
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tubules to create a greater efficiency of sodium retention. It stimulates the 
Na+/HCO3- symporter and Na+/K+ pump in the proximal tubule basolateral 
membranes (Brewster and Perazella 2004).  Ang II acts at the Na+/K+ pump in 
the medullary thick ascending limb and at the epithelial sodium channel (ENaC) 
of the cortical collecting tubules.  
 
1.3.2 Neural Effects of RAS 
 
Ang II plays a prominent role in a variety of neural mechanisms. It interacts with 
neurotransmitters and is itself considered a peptidergic neurotransmitter under 
certain conditions (McKinley, Albiston et al. 2003). It stimulates thirst centers in 
the brain, the desire for salt and is involved in vasopressin release. It facilitates 
norepinephrine release from sympathetic nerve endings and is known to 
decrease baroreflex function (DiBona 2001). Some of the central mechanisms 
are described in more detail below.  
 
1.3.3 Thirst Sensation  
 
The thirst mechanism is one way to increase fluid volume, leading to volume 
expansion and a subsequent increase in blood pressure. Stimulation of AT
1 
receptors in the brain causes an increase in water intake, salt appetite and blood 
pressure. Intracerebroventricular (ICV) administration of Ang II increases the 
dipsogenic response and blood pressure and the subfornical organ (SFO), which 
lies outside the blood-brain barrier, is reported to be involved in this dipsogenic 
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mechanism (McKinley, Albiston et al. 2003). Dehydration causes a significant 
increase in Ang II binding sites in the SFO which could make circulating Ang II 
more efficient as a thirst stimulus (Saavedra 2005).  Ablation studies showed that 
the thirst effect is facilitated by Ang II binding to receptors in the SFO and 
organum vasculosum of the lamina terminalis (OVLT) and Ang II injected into 
these forebrain areas leads to an increased blood pressure (Andersson, Eriksson 
et al. 1995) . The median preoptic nucleus (MnPO) has also been shown to be 
involved in thirst because Ang II micro-injected directly into the MnPO promotes 
drinking in rats (McKinley, Albiston et al. 2003). The MnPO is suggested to be an 
angiotensinergic synapse site that mediates thirst caused by Ang II as the SFO 
sends efferent projections to the MnPO. Projections are also sent to the 
paraventricular nucleus of the hypothalamus (PVN), which facilitates vasopressin 
production and secretion (McKinley, Albiston et al. 2003).  
 
1.3.4 Ang II and Vasopressin Release  
 
AVP, or anti-diuretic hormone (ADH), is a hormone secreted by the posterior 
pituitary gland that regulates water reabsorption in the collecting duct in kidneys 
as well as act as a potent vasoconstrictor.  It increases water permeability of the 
distal convoluted and collecting tubules by inserting aquaporin channels into the 
apical membranes of the tubules/collecting duct epithelial cells.  Circulating Ang 
II stimulates vasopressin release mainly by binding receptors in the SFO and 
possibly in the OVLT (Andersson, Eriksson et al. 1995).  The vasopressin 
response to systemic Ang II is inhibited in rats following SFO ablation (Simpson, 
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Epstein et al. 1978).  ICV injection of Ang II activates circumventricular organ 
(CVO) neurons, which directly or indirectly project to vasopressin-producing 
neurons in the paraventricular and supraoptic nuclei of the hypothalamus (SON) 
(McKinley, Albiston et al. 2003).  Coadministration of Ang II and AT
1 
receptor 
antagonist losartan decreases vasopressin secretion, further documenting Ang 
II’s role in AVP release (76).  
 
1.3.5 Ang II and the Sympathetic Nervous System  
 
The RAS and SNA are two major extrinsic regulatory mechanisms for blood 
pressure and fluid homeostasis.  Ang II activates the SNA at various levels and is 
known to be a tonic stimulus of RSNA (DiBona 2001).  Both central and 
circulating Ang II may influence SNA.  Ang II injected into the RVLM increases 
SNA and arterial pressure (Andersson, Eriksson et al. 1995).  Microinjection of 
angiotensin II receptor blockers losartan and candesartan into the RVLM 
decreased the basal level of RSNA and heart rate, with candesartan also 
decreasing BP (DiBona and Jones 2001).  Bilateral injection of Ang II receptor 
antagonists into the RVLM decreased BP similar to the decrease revealed 
subsequent to blockade of spinal sympathetic outflow (DiBona, Jones et al. 
1996).  ICV injection of losartan attenuated basal RSNA in proportion to the level 
of RAS activation (DiBona, Jones et al. 1996).  Activation of the PVN by 
bicuculline leads to an increase in arterial pressure, heart rate and RSNA, which 
is primarily mediated by excitatory angiotensinergic projections from the PVN to 
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the RVLM.  Furthermore, losartan injected into the ipsilateral RVLM decreases 
the renal sympathoexcitatory, pressor and tachycardic responses to bicuculline 
injected into the PVN (DiBona, Jones et al. 1996).  
 
As a counter to Ang II’s effects, Gironacci et al. (2004) showed that Ang-(1-7) 
decreased norepinephrine release from the hypothalamus through the Mas 
receptor, suggesting that Ang-(1–7) may decrease SNSA leading to an 
antihypertensive effect.  
 
Ang II influences renal function through central mechanisms, mainly involving 
activation of the renal sympathetic nerves.  RSNA and its arterial baroreflex 
control are mediated by changes in RAS activation. Circulating Ang II can act at 
areas such as the SFO and area postrema (AP) to modulate SNA (DiBona 
2001). Circulating Ang II acting at the AP may increase peripheral SNA through a 
direct excitatory projection from the AP to RVLM (DiBona 2001).  ICV injection of 
losartan in conscious rats did not affect basal levels of BP, but decreased basal 
RSNA suggesting that Ang II tonically influences basal levels of RSNA and its 
arterial baroreflex (DiBona, Jones et al. 1996). Brain Ang II activates AT
1 
receptors to suppress the baroreflex control of RSNA and increases sodium 
reabsorption by stimulating renal nerve activity and catecholamine release within 
the kidney (van den Meiracker and Boomsma 2003).  
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The renal sympathetic nerves innervate all the major structural elements of the 
kidney including the afferent and efferent arterioles, JG cells, mesangium, 
vascular smooth muscle cells (VSMC) and tubules (proximal, distal and 
ascending limb of loop of Henle, collecting duct), with some areas being more 
innervated than others.  There is also differential innervation of the three 
intrarenal effectors (JG cells, tubules, vasculature) such that some renal 
sympathetic nerve fibers only make contact with one of the three and some fibers 
make contact with multiple effectors (DiBona and Kopp 1997).  Low frequency 
renal nerve stimulation stimulates renin release from the JG cells via a β-1 
adrenoceptor effect, increases reabsorption of sodium and water in the tubules of 
the nephron, and causes renal vasoconstriction (Osborn, Holdaas et al. 1983).  
Activation of the renal nerves generally leads to a decrease in renal blood flow 
and GFR due to the constriction of the vasculature.  Renal nerve activation is one 
of the more important mechanisms leading to sodium retention since it increases 
sodium and water retention throughout the entire nephron and can also induce 
sodium retention by increasing renin production and by mediating the resistance 
of the afferent arterioles.  Increased renal nerve activity is thought to play a role 
in many pathologic conditions such as hypertension (Winternitz, Katholi et al. 
1980; Hendel and Collister 2006), myocardial infarction (Souza, Mill et al. 2004) 
and renal failure.  Renal denervation prevented hypertension in male SD rats 
with chronic renal failure (Campese, Kogosov et al. 1995) and in genetically 
hypertensive rats delays the development of hypertension (Liard 1977; 
Winternitz, Katholi et al. 1980; Diz, Nasjletti et al. 1982; Kline 1987).  Recently, 
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renal denervation in humans has shown to be extremely effecting in attenuating 
elevated arterial pressure in treatment-resistance patients (DiBona and Esler 
2010).  These studies highlight the importance of renal nerves in the 
manifestation and maintenance of hypertension. 
  
1.3.6 Local (Tissue) RAS  
 
The idea of local or tissue RAS was first conceptualized upon the confirmation 
that there was a separate brain RAS (local Ang II production), independent of the 
circulating RAS. It is now well established that many tissues and organs contain 
their own local RAS, including the kidney, heart, vessels, adrenal gland, 
pancreas and brain (Lavoie and Sigmund 2003; Bader and Ganten 2008).  The 
local systems seem to be regulated independently of the circulating RAS though 
interactions exist.  The actions of the tissue RAS’s may occur in the cell that 
generates the peptides (intracrine and autocrine), in neighboring cells (paracrine) 
or through the bloodstream to a specific organ or tissue (endocrine).  In the brain, 
the AT
1 
receptor is located in the SFO, OVLT, NTS, APS, PVN, CVLM, RVLM, 
dorsal medulla, the lateral parabrachial nucleus and the MnPO (Diz, Jessup et al. 
2002; McKinley, Albiston et al. 2003; Veerasingham and Raizada 2003).  These 
regions are involved in regulating cardiovascular function and/or body fluid and 
electrolyte balance.  Though all components of the RAS are located in the brain, 
not a single cell contains all of the constituents of the RAS (Saavedra 2005; von 
Bohlen und Halbach and Albrecht 2006).  
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Regulation and specific mechanisms of the brain RAS in normal physiology and 
pathophysiology are not completely understood. Studies show that the brain RAS 
activates sympathetic outflow, inhibits the baroreflex, stimulates thirst, and 
contributes to neurogenic hypertension (Steckelings, Lebrun et al. 1992; Lavoie 
and Sigmund 2003; van den Meiracker and Boomsma 2003).  In rats with chronic 
renal failure, the brain RAS is upregulated, resulting in sympathetic overactivity 
and hypertension (Nishimura, Takahashi et al. 2007).  Transgenic mice with 
increased brain Ang II production developed hypertension and an increase in salt 
appetite and drinking volume (Morimoto, Cassell et al. 2001). 
 
1.3.7 Brain RAS  
 
It is reported that there are two RASs in the brain; an endogenous system 
located within the neurons inside the blood brain barrier and a system in the 
CVOs and cerebrovascular endothelial cells that respond to circulating Ang II of 
peripheral origin (Saavedra 2005).  The two systems are interconnected and the 
brain responds to both.  Angiotensinogen is produced mainly in astrocytes 
(McKinley, Albiston et al. 2003).  Renin mRNA is present in the central nervous 
system (CNS), but concentrations are low (McKinley, Albiston et al. 2003).  High 
concentrations of ACE are located in the AP, SFO, OVLT and median eminence.  
Aminopeptidase A and N are both located in the rodent brain. Ang I, Ang II, Ang 
III and Ang-(1-7) have been discovered in brain tissue, however Ang III and Ang-
(1-7) are found in very low concentrations (McKinley, Albiston et al. 2003).  
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1.3.8 Kidney RAS  
 
All of the RAS components are present within the kidney with 
compartmentalization in the tubules and interstitium as well as intracellular 
accumulation (Kobori, Nangaku et al. 2007).  In fact, it is reported that there are 
two distinct intrarenal RASs; vascular (renal vessels, arterioles and glomeruli) 
and tubulointerstitial (proximal tubules and associated interstitium). Intrarenal 
Ang II, which can be formed independent of the circulation, may also be a result 
of circulating Ang II that is internalized into proximal tubule cells by the AT
1 
receptor.  In addition, Ang II may be formed from systemically delivered Ang I 
(Navar, Harrison-Bernard et al. 1999).  Angiotensinogen is located mostly in the 
proximal tubule cells and can be secreted directly into the tubule lumen (Navar, 
Prieto et al. 2011).  In general, renin from the JG cells is the primary source of 
both circulating and intrarenal renin.  However, renin is also found in other areas 
of the kidney and is produced by the proximal tubule cells, as well as the distal 
nephron segments. Ang I and Ang II formation in the tubule lumen may occur 
subsequent to angiotensinogen secretion because some renin is filtered and/or 
secreted from juxtaglomerular or proximal tubule cells.  ACE is located on the 
proximal tubule brush border and converts Ang I to Ang II (Kobori, Nangaku et al. 
2007).  ACE2 is present in renal endothelial and tubule cells and in glomerular 
podocyte and mesangial cells (Donoghue, Hsieh et al. 2000; Reich, Oudit et al. 
2008).  Previous work demonstrates that Ang I and Ang II are located with renin 
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in the juxtaglomerular apparatus cells and vascular smooth muscle cells of the 
afferent arteriole (Navar, Prieto et al. 2011).  However, Ang I and Ang II are 
mainly located in the tubular and interstitial fluid compartments (Navar, Prieto et 
al. 2011).  The AT
1 
receptor is extensively dispersed throughout the kidney.  It is 
located in the vascular smooth muscle cells of the afferent and efferent arterioles, 
glomeruli (mesangial cells and podocytes) and proximal tubule cells (brush 
border and basolateral membranes).  Receptor subtypes are also found in the 
juxtaglomerular and macula densa cells, thick ascending limb, distal tubules, 
vasa recta, arcuate arteries and cortical collecting ducts (Carey and Siragy 2003; 
Kobori, Nangaku et al. 2007).  The distribution of the two AT
1 
receptor subtypes 
in rodents is different with the AT
1A 
subtype being the more prevalent of the two. 
The AT
1A 
is present in all nephron segments and AT
1B 
is more abundant than 
AT
1A 
in the glomerulus (66). The AT
2 
receptor is present in the afferent arteriole, 
mesangium, proximal tubule, collecting ducts, parts of the renal vasculature, 
interstitial cells and in glomerular endothelial and epithelial cells (Bader and 
Ganten 2008).   
 
The intrarenal RAS is regulated differently than the circulating RAS as shown by 
the fact that proximal tubule angiotensinogen, collecting duct renin and tubular 
AT
1 
receptors are increased by intrarenal Ang II (Kobori, Nangaku et al. 2007).  
Intrarenal RAS activation may contribute to hypertension, renal injury, diabetes 
and metabolic syndrome.  Ang II produced in the kidney directly induces 
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podocyte injury and apoptosis through AT
1 
receptor activation independent of 
hemodynamic changes (Kobori, Nangaku et al. 2007).  Ang II induces 
proliferation of glomerular endothelial cells, mesangial cells and fibroblasts 
(Rüster and Wolf 2006).  Additionally, hyperglycemia, proteinuria and renal injury 
activate the intrarenal RAS (Rüster and Wolf 2006).  
 
Inhibition of the RAS has proven to be renoprotective against diseases other than 
hypertension.  The American Diabetes Association suggest that ACE inhibitors 
and angiotensin II receptor blockers (ARBs) be considered as first-line therapy to 
slow renal disease progression in hypertensive and type 2 diabetic patients 
(Vejakama, Thakkinstian et al. 2012).  In hypertensive, type 2 diabetic patients, 
irbesartan delayed the increase in serum creatinine 24% more slowly than the 
placebo group and 21% slower than the group that received the calcium channel 
blocker amlodipine (Rossing, Schjoedt et al. 2005).  This renoprotective effect 
was independent of the blood pressure lowering effect (Lewis, Hunsicker et al. 
2001) as ARBs have been shown to benefit normotensive diabetic patients as 
well (Coyle, Gardner et al. 2004).  ACE inhibitors decrease mesangial expansion, 
glomerulosclerosis, loss of glomeruli, tubular atrophy, interstitial fibrosis and 
proteinuria (Gansevoort, Sluiter et al. 1995; Ferder, Inserra et al. 2003).  
Proteinuria is also decreased in the presence of AT
1 
receptor blockers (Mizuno, 
Sada et al. 2006).  Losartan and enalapril reduced glomerular and 
tubulointerstitial fibrosis, tubular atrophy and increased the number mitochondria 
and improved mitochondrial function (Ferder, Inserra et al. 2003).   
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The RAS has been suggested to play a pathogenic role in the development of 
hypertension in Okamoto-Aoki Spontaneously Hypertensive Rat (SHR).  These 
RAS implications are directly related in part to activation of sympathetic nerve 
activity. Numerous studies have demonstrated that administration of either 
angiotensin-converting ACE inhibitors or angiotensin receptor antagonists to 
immature SHRs prevents development of hypertension (Madeddu, Anania et al. 
1995) .  In the SHR, brain levels of Ang II and renin are elevated after the onset 
of adult hypertension (Phillips and Kimura 1988), hypothalamic angiotensinogen 
mRNA is more abundant (Yongue, Angulo et al. 1991), and SHRs exhibit 
elevated AT1r mRNA in the brain and kidney compared to normotensive Wistar 
Kyoto (WKY) rats (Raizada, Sumners et al. 1993; Cheng, Wang et al. 1998).  
Subsequently, losartan, a potent AT1r antagonist, normalizes blood pressure in 
SHRs when delivered intravenously (IV) or ICV (Medina, Cardona-Sanclemente 
et al. 1997).  In addition to pharmacological blockade, Gyurko et al. (1993) 
demonstrated that inhibiting the brain RAS by antisense inhibition of 
angiotensinogen and AT1 receptor genes lowers blood pressure in adult SHRs, 
potentially linking genetic contributions of the RAS to hypertension.  
Abnormalities in AT1r function have been linked to several pathological 
conditions such as hypertension, cardiac and renal hypertrophy, and proliferation 
of vascular smooth muscle cells. Each of these pathologies alone or together 
may critically contribute to the onset and maintenance of hypertension.  Taken 
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together, SHRs exhibit an exacerbated RAS, which in turn, plays a role in 
development of elevated arterial pressure and propagation of hypertension. 
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Figure 1.4: Overview of the renin-angiotensin system (RAS). 
AGT indicates angiotensinogen; Ang, angiotensin; ACE, 
angiotensin-converting enzyme; ACE2, angiotensin-converting 
enzyme 2; AT1R, angiotensin type 1 receptor; AT2R, 
angiotensin type 2 receptor; MasR, Mas (Conti, Cassis et al. 
2012) 
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1.4 Nuclear Genetics and Genomics of Spontaneous Hypertension 
 
Significant effort has been devoted to defining the pathogenesis of blood 
pressure variation.  The difficulty in defining the causes of hypertension from 
physiological studies alone motivated the application of genetic approaches to 
hypertension. Identification of genes underlying blood pressure variation has the 
capacity to define primary physiologic mechanisms underlying this trait, thereby 
clarifying disease pathogenesis, identifying pathways and targets for improved 
therapeutic intervention, providing opportunity for preclinical diagnosis, and 
allowing treatment tailored to individual patients. There is substantial evidence for 
genetic influence on blood pressure. Twin studies document greater 
concordance of blood pressures of monozygotic than dizygotic twins (Feinleib, 
Garrison et al. 1977) and population studies demonstrate greater similarity of 
blood pressure within families than between families (Longini, Higgins et al. 
1984). This familial aggregation of blood pressure is not simply attributable to 
shared environmental effects since adoption studies show greater concordance 
of blood pressure among biological siblings than adoptive siblings living in the 
same household (Biron, Mongeau et al. 1976) (Rice, Vogler et al. 1989). Single 
genes can impart large effects on blood pressure as demonstrated by rare 
Mendelian forms of high and low blood pressure (Lifton 1996).  Although these 
Mendelian traits have quantitatively large effects in affected individuals, they are 
quite rare and likely account for a very small fraction of the variation in blood 
pressure in the human population (Lifton, Gharavi et al. 2001). 
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The polygenic nature of essential hypertension and its dependence on 
environmental factors complicate the identification of causative genetic factors 
(Garrett, Dene et al. 1998).  Significant progress has been made to map the 
genes involved in blood pressure regulation.  Genome scans have been carried 
out in rats, mice and humans and have revealed several potential chromosome 
regions that may contain genes involved in the pathogenesis of spontaneous 
hypertension.  Molecular genetic analysis proves that BP regulation is polygenic 
and there is good evidence for several BP related quantitative trail loci (QTL) on 
nearly every rat chromosome (Deng, Dene et al. 1994; Schork, Krieger et al. 
1995; Hopkins and Hunt 2003; Laulederkind, Hayman et al. 2013).  Linkage 
studies in populations derived from the SHR indicate potential BP QTL.  
Recently, Atanur et al. (2010) sequenced the SHR/Olalpcv genome, identifying 
3.6 million high quality SNPs between the SHR/Olalpcv and BN reference 
genome.  Genomic regions containing genes that have been previously mapped 
as cis-regulated expression (QTL) contained several SNPs, short indels, and 
larger deletions which suggests potential functional effects on gene expression.  
Atanur et al. found 688 genes that overlap with regions showing copy number 
variation (CNV) that represent genes for immunological, neurological or 
mechanical function.  The high statistical significance of these functional variants, 
coupled with the known metabolic, cardiovascular and neurobehaviorial 
phenotypes described in the SHR (Okamoto and Aoki 1963), suggests alteration 
of these gene classes may directly relate to the phenotypes manifested by SHR-
derived strains (Rapp 2000).  This sequence information supports previous 
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studies of experimental crosses and congenic strains that led to the identification 
of CNV in rat Cd36 gene as a cause of CD36 deficiency, insulin resistance, 
dyslipidemia, and hypertension in the SHR strain (Aitman, Glazier et al. 1999; 
Pravenec, Landa et al. 2001; Pravenec, Churchill et al. 2008).  This highlights the 
potential functional significance of other CNVs detected in the SHR genome.   
 
 
1.4.1 Renin-Angiotensin System Genes and Hypertension 
 
With the abundance of knowledge on the role of both circulating and tissue RAS 
in BP control, it is hypothesized that genetic variability in one or more of the RAS 
components could account for the pathogenesis of hypertension.  A large 
number of patients with hypertension and cardiovascular disease are on ACE 
inhibitors or AT1r antagonists.   Recognizing a potential genetic influence on 
protein expression would be vital to the treatment and prevention of essential 
hypertension.   The mouse renin gene (Ren) was the first gene of the RAS to be 
cloned (Burnham, Hawelu-Johnson et al. 1987).  Several investigators have 
established transgenic models expressing the mouse Ren-2 gene (mRen-2).   
High expression of the transgene has been shown to cause severe hypertension, 
associated with increased renin activity and local Ang II formation, while 
suppressing plasma RAS (Rothermund and Paul 1998). Restriction mapping and 
linkage analysis have been used to study the association of renin and 
hypertension, but whether the renin locus is associated with hypertension is still 
under debate.  Cloning of the human genes coding for angiotensinogen (Agt) 
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(Jeunemaitre, Soubrier et al. 1992), angiotensin-converting enzyme (ACE) 
(Rigat, Hubert et al. 1990) and the AT1 receptor (Agtr1a/b) (Bonnardeaux, Davies 
et al. 1994) has led to the discovery of several polymorphisms that may play a 
role as risk factors for hypertension.  Higher levels of angiotensinogen have been 
demonstrated to be associated with higher levels of Ang II (Walker, Whelton et 
al. 1979).   In addition, transgenic mice with overexpression of a rat 
angiotensinogen gene develop hypertension, and knockout mice with a disrupted 
gene and absent production of angiotensinogen develop low BP (Jeunemaitre, 
Soubrier et al. 1992).  
 
In 1990, Rigat et al (1990) produced evidence for an insertion/deletion (I/D) 
polymorphism (287bp insert/deletion) in intron 16 of the ACE gene was strongly 
associated with circulating ACE concentrations.  In individuals that were 
homozygous for the D allele (D/D), plasma ACE concentrations were twice those 
of persons homozygous for I allele (I/I).  Zhu et al. (Zhu, McKenzie et al. 2000)  
later reported that the functional mutation was not the I/D variant, but a variant 
downstream that exists in linkage disequilibrium that is responsible for changes 
in plasma ACE levels.  Nevertheless, there is significant evidence that the ACE 
gene controls plasma ACE concentrations and therefore could have a causal 
relationship with hypertension.   
 
For the Agtr1a/b gene, a SNP has been described in which either adenine (A) or 
a cytosine (C) base (A/C tranversion) in position 1166 in the 3’ untranslated 
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region of the gene (Joe and Garrett 2005).  The physiological importance of this 
polymorphism is uncertain because of its location in the untranslated region, 
however several studies have shown that it was associated with hypertension 
(Joe and Garrett 2005), left ventricular hypertrophy (Takami, Katsuya et al. 
1998), coronary artery disease and myocardial infarction (Bonnardeaux, Davies 
et al. 1994), and progression of diabetic nephropathy (Tomino, Makita et al. 
1999).  The silent A1166C SNP has been associated with severe forms of 
hypertension, and in particular in resistant hypertensive patients taking two or 
more antihypertensive drugs (Bonnardeaux, Davies et al. 1994; Kainulainen, 
Perola et al. 1999).  However, the relationship between this SNP and BP shows 
great diversity within human populations (Baudin 2002).  The most likely scenario 
is that the polymorphic transversion in not functional, but may occur in linkage 
disequilibrium with an unidentified functional variant (Bonnardeaux, Davies et al. 
1994).   
 
Although significant progress has been made, the exact form of the underlying 
genetic mechanisms remains unanswered.  Multiple approaches will be needed 
to achieve this assignment; however, the sequencing of the SHR nuclear 
genome by Atanur et al. (2010) will provide a great source for complete 
functional elucidation between hypertensive and normotensive rats of SHR origin 
at the molecular level.  This provides substantial insight to the genetic 
components of human essential hypertension.   It is the hope that by identifying 
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nuclear genes contributing to hypertension, that we can switch from treatment to 
prevention of hypertension and cardiovascular disease.   
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1.5 Mitochondrial Genomics/Dynamics and Hypertension 
 
Eukaryotic cells contain a number of organelles with specialized functions like the 
mitochondria.  Mitochondria are broadly known as double-membrane-bounded 
organelles, which perform a number of indispensable functions for the life of most 
eukaryotic cells.  Their main function is the production of energy in the form of 
ATP via the citric acid cycle and the oxidative phosphorylation system 
(OXPHOS),  but they are also involved in the biosynthesis of many metabolites 
like pyrimidines,  amino  acids  or cellular iron sulphur cluster proteins (Bereiter-
Hahn 1990; Attardi, Yoneda et al. 1995; Lill, Diekert et al. 1999). Mitochondria 
also control the ability of the cell to generate and detoxify reactive oxygen 
species (ROS) (Nicholls, Vesce et al. 2003).  Beside their role as ATP 
generators, mitochondria  have  also the ability to remove Ca2+  ions out of the 
cytosol and accumulate them in their matrix (Deluca and Engstrom 1961).  The 
release of mitochondrial pro-apoptotic factors like cytochrome c into the 
cytoplasm can induce a signaling cascade, which plays a prominent role in 
apoptotic cell death (Hengartner 2000). 
 
The  citric  acid  cycle,  which takes place in the mitochondrial matrix, is a central 
metabolic pathway involved in the catabolic oxidation of substrates (Krebs 1970).  
Acetyl-CoA, which is generated by the decomposition of nutrients such as 
glucose, transfers two carbon acetyl groups to oxaloacetate to generate citrate. 
The citrate is metabolized through a series of chemical transformations and 
releases two carboxyl groups as CO2. The energy-rich electrons generated by 
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the cycle are transferred to NAD+/NADP+ and FAD+ to form NADH/NADPH and 
FADH2.  Several substances like NADH, ATP and Ca2+ regulate the citric acid 
cycle (Krebs 1970).   
 
The electrons generated via the citric acid cycle are transferred to the 
multisubunit enzyme complexes of the respiratory chain.  The OXPHOS is 
embedded in the inner mitochondrial membrane.  Functionally, it is composed of 
the five enzyme complexes: NADH dehydrogenase (Complex  I),  succinate 
dehydrogenase (Complex  II), cytochrome bc1 complex (Complex  III), 
cytochrome c oxidase (Complex IV, COX) and ATP synthase (Complex V) as 
well as the two electron carriers coenzyme Q and cytochrome c (Hatefi 1985). 
The electrons are transferred to oxygen to generate water at Complex IV.  The 
transport of electrons via the respiratory chain generates a proton gradient 
across the membrane which is used to synthesize ATP by Complex V (Hatefi 
1985). 
 
Molecular genetics research and hypertension has been primarily focused on the 
nuclear genes (nDNA), despite the fact that mitochondria are present in multiple 
copies in each cell, have their own genome, and mitochondrial dysfunction has 
recently been implicated in a wide variety of genetic disorders (Aitman, Glazier et 
al. 1999; Taylor and Turnbull 2005).   Mitochondrial DNA is transmitted through 
the oocyte’s cytoplasm at fertilization, hence, are nearly strictly maternally 
inherited.  Alterations in mitochondrial function are observed in conjunction with 
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increase in age and the development of hypertension in rodents and humans 
(Hofmann, Jaksch et al. 1997; Shin, Tanaka et al. 2000; Schwartz, Duka et al. 
2004; Chan, Wu et al. 2009; Kumarasamy, Gopalakrishnan et al. 2010). 
Mitochondria are the principal generators of cellular ATP by OXPHOS.  
Mammalian mtDNA encodes 37 genes, including 13 polypeptide genes, all of 
which encode essential components of OXPHOS.  It also encodes the 12S and 
16S ribosomal RNA (rRNA) genes and the 22 transfer RNA (tRNA) genes 
required for mitochondrial protein synthesis (Figure 1.5).  The rat mtDNA 
genome varies between 16,307 and 16,315 bp in size.  The size variation is due 
to insertions/deletions in the replication origin, D-loop, 16S rRNA, and NADH 
dehydrogenase subunit 2 (Schlick, Jensen-Seaman et al. 2006).  Each 
mitochondrion contains one to ten copies of its genome and each cell 
encompasses hundreds to thousands copies of mitochondria. The faster rate of 
mtDNA replication, however, is not without consequences, particularly, in an 
environment that is high in reactive oxygen species (ROS). The rare error rates 
of DNA replication and editing enzymes increase in the presence of oxidative 
modified nucleotides and enzymes. Hence, mtDNA has ~16 times higher 
mutation accumulation rate than the nDNA (Richter, Park et al. 1988). Mutations 
could initiate a vicious cycle of impaired mitochondrial functions, increased ROS, 
higher error rates of DNA polymerases and editing enzymes and further 
accumulation of mutated mtDNA.  Given the presence of thousands of copies of 
mtDNA in each cell, mutations generate an admixture of wild type and mutant 
mtDNA, which is referred to as heteroplasmy, as opposed to homoplasmy, when 
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all copies of mtDNA are identical. Heteroplasmy in mtDNA in somatic cells, as 
the mitochondria replicates, increases with age. Accordingly mitochondrial 
mutations and dysfunctions have been implicated in various age-dependent 
phenotypes including cellular senescence and metabolic disorders. 
 
Base substitutions in mtDNA protein synthesis genes can result in multisystem 
disorders with a wide range of symptoms (Shin, Tanaka et al. 2000; Schwartz, 
Duka et al. 2004; Wallace 2005).  Recently, Schlick et al. (2006) sequenced the 
mtDNA of 10 commonly used inbred rat strains.  Analysis showed 11 single 
nucleotide polymorphisms (SNPs) within the tRNA genes, 6 in the 12S  rRNA, 
and 12 in the 16S rRNA including 3 indels.  Also, 14 SNPs and 2 indels were 
found in the D-loops.  Pravenec et al. (Pravenec, Churchill et al. 2008) 
investigated whether naturally occurring variation in the mitochondrial genome of 
SHRs and BN rats could be linked to risk factors for type 2 diabetes.  Sequence 
analysis revealed distinct differences between the 2 strains, revealing 
polymorphisms of functional significance in seven of 13 mRNA genes, five of 22 
tRNA genes and both rRNA genes.  The mRNA variants were predicted to cause 
amino acid substitutions in mitochondrial cytochrome oxidase subunit 1, ATP 
synthase subunit 6, ATP synthase subunit 8, cytochrome b, NADH 
dehydrogenase subunit 2, and NADH dehyrogenase 6.  Some of these amino 
acid substitutions are located within 0-3 residues of mutation sites known to be 
associated with human diseases (Pravenec, Churchill et al. 2008).  Variations in 
the tRNA genes were also shown to be closely located to human mutation sites 
 
 
42 
 
associated with mitochondrial encephalopathy (Elo, Yadavalli et al. 2012).  
Recently, reports of mitochondrial tRNA mutations were observed in a Chinese 
population with essential hypertension (Li, Liu et al. 2009; Liu, Li et al. 2009).  
Additionally, Wilson et al. (2004) describe a causal relationship between a 
T4921C transition SNP, which lies in the mitochondrial tRNAlle gene and 
hypertension.  The genetic association of mtDNA variants and tRNA mutations to 
type 2 diabetes and hypertension directly implicated mitochondrial defects to the 
etiology of cardiovascular disease and metabolic syndrome (Wallace 2005). 
Taken together, there is significant evidence of mtDNA mutations and altered 
mitochondrial genetic expression that may play a significant role in 
cardiovascular disease phenotypes.   
 
The viability of individual electron transport chain (ETC) subunits and the 
potential for disease has been evaluated.  Altered function of complex I has been 
linked to cardiovascular disease (Antonicka, Ogilvie et al. 2003; Lopez-
Campistrous, Hao et al. 2008).  Lopez-Campistrous et al. revealed defects in 
complex I in the brainstem of SHR, resulting in increased reactive oxygen 
species production, decreased ATP synthesis and impaired respiration in 
hypertension (Lopez-Campistrous, Hao et al. 2008).  Altered function of complex 
III, a major site of superoxide formation and ROS production, may play an 
important role in renal mitochondrial ETC dysfunction and cardiovascular 
disease.  Similar to these findings, Das et al. (1990) reported that the regulation 
of ATP synthase is abnormal in SHR cardiac cells, as demonstrated by the 
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inability to respond to acute increases in energy demand compared to cells from 
normotensive rats .  Taken together, the altered function of ETC subunits derived 
from decreased kidney-specific mt-gene expression may have several 
implications to the development of hypertension. 
 
To date, however, it is clear that phenotypes that may arise from mtDNA 
mutations are not uniform, and can be influenced by both environmental factors 
as well as the nuclear genome.  Only 13 of the  proteins needed to assemble the 
electron transport chain are coded by the mitochondrial genome.  The remaining 
proteins are coded by the nuclear genome and transferred to the mitochondria.  
This interaction may have profound effects on disease phenotypes.  For 
example, mutations in the nDNA encoded hepatocyte nuclear factor-1 alpha 
(HNF-1α) are associated with post-pubertal diabetes, dislipidemia and 
hypertension (Wallace 1999).  HNF-1 is also important in regulating nDNA-
encoded mitochondrial gene expression (Wang, Maechler et al. 2000).  Patients 
with type II diabetes show a downregulation in the expression of nDNA encoded 
mitochondrial genes associated with mitochondrial biogenesis and transcription 
(Patti, Butte et al. 2003).  In the SHR, the gene encoding mitochondrial coupling 
factor 6 was evaluated.  Osanai et al. (2001) reported that the genetic expression 
and plasma concentration of coupling factor 6 was significantly higher in SHRs 
compared with normotensive controls.  Functional analysis suggests that it acts 
as a potent endogenous vasoconstrictor as a circulating hormone, and thus a 
potential factor in the propagation of hypertension.  Circulating coupling factor 6 
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is also elevated in human hypertensive patients compared with normotensive 
subjects (Osanai, Sasaki et al. 2003).  Taken together, these findings suggest 
that mitochondrial dysfunction of both mitochondrial and nuclear origin may play 
a significant role in the pathophysiology of arterial blood pressure regulation and 
development of hypertension (Figure 1.7). 
 
The nuclear pathway that regulates mitochondrial transcription and biogenesis is 
well established (Ventura-Clapier, Garnier et al. 2008).  Peroxisome proliferator-
activated receptor gamma coactivator 1 alpha (PGC-1α) plays a central role in 
regulating mitochondrial content and function within cells, because of its ability to 
co-activate and augment several promoters of nuclear-encoded mitochondrial 
genes, as well as regulating mitochondrial transcription via the NRF-Tfam 
(Nuclear respiration factor-Transcription factor A mitochondria) pathway (Figure 
1.6) (Wu, Puigserver et al. 1999).  PGC-1α regulates NRF-dependent 
transcription, increases expression of both mitochondrial and nuclear encoded 
genes of oxidative phosphorylation and induces mitochondrial biogenesis 
(Scarpulla 2002).  Decreased PGC-1α  expression has been shown to decrease 
expression of NRF-dependent genes, leading to metabolic disturbances 
characteristic of type II diabetes (Patti, Butte et al. 2003).  This linear coordinated 
reduction of nuclear transcription factors, that ultimately leads to decreased 
mitochondrial gene transcription appears to play a role in metabolic syndrome, 
however, it’s role in the development of hypertension is largely unknown.  
Additionally, it has been shown that metabolic functions are controlled by PGC-
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1α  in a tissue specific manner in brown fat, muscle and liver (Puigserver 2005), 
however kidney regulation of  PGC-1α  and its effectors is unknown. 
 
Mitochondrial dysfunction contributes to the pathophysiology of hypertension, 
renal disease, as well as other cardiovascular diseases.   Significant evidence 
indicates that the RAS plays a role in developing mitochondriopathy.  AngII 
stimulates mitochondrial oxidant release both directly and indirectly, leading to 
energy metabolism depression, and potentially modification of gene expression, 
ultimately contributing to cardiovascular-related pathologies (de Cavanagh, 
Inserra et al. 2007). Dikalova et. al showed that mitochondrial superoxide was 
directly related to the development of hypertension, and that targeting of 
mitochondrial superoxide scavenging significantly attenuates the development of 
the disease (Dikalova, Bikineyeva et al. 2010).  Additionally, de Cavanagh et al. 
demonstrated that oxidant stress is associated with mitochondrial dysfunction in 
the SHR, and that blocking AngII with losartan provided mitochondrial-antioxidant 
actions that reversed mitochondrial dysfunction and renal impairment (de 
Cavanagh, Toblli et al. 2006).  AngII can promote mitochondrial oxidative stress 
indirectly by stimulating both nitric oxide (NO) production and NAD(P)H oxidase-
derived superoxide, which in turn enhances peroxynitrite  formation (Pueyo, 
Arnal et al. 1998).  Substantial evidence has shown that NAD(P)H oxidase 
derived reactive oxygen species are important mediators of AngII signaling 
(Figure 1.7) (de Cavanagh, Inserra et al. 2007).  ROS has been shown to play 
an important role in the physiological and pathophysiological process in the 
 
 
46 
 
central nervous system, and has been linked to activation of sympathetic nerve 
activity (Gao, Wang et al. 2004) . SHRs exhibit increased NAD(P)H driven O2- 
generation in resistance and aortic vessels (Rodriguez-Iturbe, Zhan et al. 2003; 
Tanito, Nakamura et al. 2004), associated with NAD(P)H oxidase subunit 
overexpression and enhanced oxidase activity (Shokoji, Nishiyama et al. 2003; 
Kishi, Hirooka et al. 2004).  Several polymorphisms in the promoter region of the 
p22phox gene have been identified in the SHR (Zalba, San Jose et al. 2001), and 
an association between p22phox gene polymorphism and NAD(P)H oxidase 
mediated O2- production in the vascular wall of humans with hypertension also 
has been established (Moreno, San Jose et al. 2003). Additionally, increased 
expression of p47phox has been reported in the renal vasculature, macula densa 
and distal nephron of young SHRs, suggesting renal NAD(P)H oxidase 
upregulation in kidney structures precedes development of hypertension, that 
again may be related to altered RAS activity (Kishi, Hirooka et al. 2004).  The 
role played by angiotensin II in developing mitochondriopathy has been 
advanced recently by Benigni et al. (Benigni, Corna et al. 2009).   Deletion of the 
Agtr-1a gene resulted in the reduced age-related cardio-renal complications, 
improved mitochondrial biogenesis, and increased longevity in mice.  Treatment 
with antioxidants, superoxide dismutase (SOD) mimetics, and AT1r blockers 
decrease vascular O2- production and attenuate development of hypertension in 
the SHR and stroke-prone SHR (Park, Touyz et al. 2002; Rodriguez-Iturbe, Zhan 
et al. 2003; Shokoji, Nishiyama et al. 2003).  Taken together, these findings 
suggest that oxidative stress plays an important role in genetic hypertension and 
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involves NAD(P)H oxidase activity that is regulated, in part, by the AT1 receptor 
and possibly AT1r genetic expression. 
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Figure 1.5: Mamalian mitochondrial genome.  Mammalian mtDNA 
encodes 37 genes, including 13 polypeptide genes, all of which 
encode essential components of OXPHOS.  It also encodes the 
12S and 16S rRNA genes and the 22 tRNA genes required for 
mitochondrial protein synthesis (Leigh-Brown, Enriquez et al. 
2010). 
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Figure 1.6: Nuclear-mitochondrial pathway driving mtDNA transcription 
and biogenesis.  This well known pathway may be regulated in a tissue-
specific manner, depending on the energetic needs of that tissue.   
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Figure 1.7: Proposed role of redox-dependent cross talk between 
mitochondria and NADPH oxidases (NOXs) in vascular and renal 
dysfunction in hypertension. CVD, cardiovascular disease; NO, nitirc oxide; 
ONOO−, peroxynitrite; eNOS, endothelial NO synthase; GPx, glutathione 
peroxidase, Trx2, thioredoxin 2; mCat, catalase targeted to mitochondria; 
mKATP, ATP-sensitive K+ channel; ΔΨm, mitochondrial transmembrane 
potential (Dikalov 2013)    
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Rationale, Overall Hypothesis and Specific Aims 
 
Primary or essential hypertension is regarded as a multi-factorial disease, 
influenced by both genetic makeup and environmental conditions. Though 
several (~300) genetic loci have been identified for hypertension in the rat 
(Hilbert, Lindpaintner et al. 1991; Schork, Krieger et al. 1995; Laulederkind, 
Hayman et al. 2013), the exact form of the underlying genetic mechanism 
remains unanswered.  In addition to being polygenic, hypertension is thought to 
be polygenomic, with significant evidence supporting the relationship between 
mtDNA dysfunction and cardiovascular disease (Wilson, Hariri et al. 2004; de 
Cavanagh, Inserra et al. 2007; Chan, Wu et al. 2009).  Additionally, significant 
data from our lab and others have documented that angiotensin II and the renin-
angiotensin system play a critical role in maintenance of arterial blood pressure 
and, that this hormonal system is elevated in several experimental models of 
hypertension, as well as human essential hypertension.  Presented in this body 
of work is evidence of renal intrinsic and extrinsic mechanisms, including specific 
humoral, genetic and genomic mechanisms that appear to play a role in the 
manifestation and maintenance of spontaneous hypertension.  This work will be 
laid out in the following aims: 
 
Specific Aim 1  established a unique rodent colony (BN/SHR-mtSHR) 
to attempt to isolate nuclear and mitochondrial genes, and their potential 
interaction with the renin-angiotensin system that may be causal to 
hypertension in BN/SHR-mtSHR 
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Specific Aim 2 determined tissue angiotensin II, type 1 receptor 
(AT1r) gene and protein expression in normotensive (NT) and hypertensive 
(HT) BN/SHR-mtSHR.   
• Evaluate tissue-specific Agtr1a mRNA expression and incidence 
of hypertension in BN/SHR-mtSHR 
• Evaluate kidney- and hypothalamic- specific AT1 protein 
expression and incidence of hypertension in BN/SHR-mtSHR 
 
Specific Aim 3 evaluated sodium sensitivity and renal function in 
hypertensive and normotensive BC5 sibxsib BN/SHR-mtSHR. 
• Characterize renal function, pressure-natriuresis and diuresis in 
normotensive and hypertensive BN/SHR-mtSHR 
 
Specific Aim 4 evaluated tissue-specific nuclear and mitochondrial 
genes involved in oxidative phosphorylation and their role in spontaneous 
hypertension in BN/SHR-mtSHR.  
• Evaluate tissue-specific mitochondrial gene expression and 
incidence of hypertension in BN/SHR-mtSHR 
• Evaluate tissue-specific gene expression of nuclear regulatory 
factors for mitochondrial transcription and regulation 
• Characterize kidney-specific OXPHOS using cytochrome 
oxidase staining in normotensive and hypertensive BN/SHR-
mtSHR 
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CHAPTER 2 
SPONTANEOUS HYPERTENSION: THE SPONTANEOUSLY HYPERTENSIVE 
RAT & DEVELOPMENT OF BN/SHR-mtSHR CONPLASTIC RAT MODEL 
 
 
Jason Andrieu Collett, Jeffrey L. Osborn 
 
 
 
 
 
Abbreviations used: BN, Brown Norway rat; WKY, Wistar Kyoto rat; SAP, 
systolic arterial pressure  
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2.1 Introduction: Development of the Spontaneously Hypertensive Rat 
 
The various mechanisms underlying human hypertension have been difficult to 
study as there is individual variation in the polygenetic/polygenomic disposition 
and environmental factors that are difficult to differentiate from each other.  The 
most commonly used model of experimental hypertension is the Spontaneously 
Hypertensive rat (SHR). Okamoto-Aoki SHRs are descendants of an outbred 
Wistar male (WKY) with spontaneous hypertension from a colony in Kyoto, 
Japan (Okamoto and Aoki 1963).  Briefly, A male rat with spontaneously high 
systolic blood pressures of 150 to 175 mmHg persisting for more than one month 
and a female rat with elevated systolic blood pressures (130 to 140 mmHg), were 
mated to obtain F1 rats. Of these F1 rats, males and females with hypertension, 
as defined as systolic BP > 150mmHg persisting for more than a month were 
mated to produce F2 generation rats. The procedure was repeated to obtain F3, 
F4, F5 and F6 rats totaling 380 animals.  The incidence of the spontaneous 
occurrence of hypertension increased, and the development of hypertension 
occurred at younger ages from generation to generation.  The incidence of 
severe hypertension (SYS>200mmHg) increased with each generation, so that 
among male animals it increased from only 9% in F2 to 35% in F3, 42% in F4, 
and 56% in F5, and in female animals from 3% in F2, 16% in F3, 33% in F4, and 
37% in F5 (Okamoto and Aoki 1963).  From 1968, this inbred strain of SHRs was 
further developed in the USA and elsewhere (Kurtz and Morris 1987). The 
various colonies of SHR are pre-hypertensive for the first 6–8 weeks of their lives 
with systolic blood pressures around 100–120 mmHg (Adams, Bobik et al. 1989), 
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and then hypertension develops over the next 12–14 weeks(Doggrell and Brown 
1998).  As in humans, hypertension develops more rapidly and becomes more 
severe in male than female SHR (Iams and Wexler 1979). In vivo studies have 
shown that, in the early stages of hypertension, SHRs have an increased cardiac 
output with normal total peripheral resistance. As the SHR progresses into the 
established hypertension state, the cardiac output returns to normal and the 
hypertrophied blood vessels produce an increase in the total peripheral 
resistance.  
 
Researchers in hypertension have commonly used SHRs which have, within 
each colony, uniform polygenetic disposition that influence the cardiovascular 
system.  It was, and continues to be the hope of geneticists and physiologists 
that the SHR will be pivotal in identifying genes contributing significantly to the 
pathophysiology of hypertension.  The nuclear loci causal to chronic elevated 
arterial pressure have been extensively investigated in the SHR (Kurtz, Casto et 
al. 1990; Ye and West 2003; Atanur, Birol et al. 2010; Pravenec and Kurtz 2010; 
Yamamoto, Okuzaki et al. 2013).  Translationally, the SHR follows the same 
progression of hypertension as human hypertension with pre-hypertensive, 
developing and sustained hypertensive phases with each phase lasting at least 
several weeks (Folkow 1993). However, the SHR differs from human 
hypertension in that SHRs reproducibly develop hypertension in young adulthood 
rather than in middle age as in humans.  SHRs have a defined “pre-hypertensive 
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state”, which makes the model invaluable to be used in studies of the cause and 
development of hypertension.  
 
The WKY controls were established later, in 1971, as a normotensive control 
strain by the National Institutes of Health (USA) as an inbreed of the Wistar 
Kyoto colony via brother×sister mating (Kurtz and Morris 1987). The degree of 
genetic difference between the SHR and WKY strains and within different 
colonies of each strain is substantial and comparable to the extreme variability 
that exists between human populations and thus unlikely to be related solely to 
hypertension (Johnson, Ely et al. 1992; St Lezin, Simonet et al. 1992). 
Differences between SHRs and Wistar normotensive rats other than WKY may 
be more likely to be hypertension-related than differences between SHR and 
WKY because the SHRs were derived from the WKY, hypertension may develop 
spontaneously in the WKY, and the WKY may share some of the genes 
responsible for hypertension with the SHR (Louis and Howes 1990).  
 
The SHR has been shown to exhibit lower blood pressure when administered the 
most common antihypertensive medications (Pinto, Paul et al. 1998).  Thus, it is 
not surprising that SHRs have been used extensively and successfully for 50 
years to test compounds for their effectiveness in lowering blood pressure, and to 
study the mechanisms of established hypertension.  
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To investigate mechanisms underlying spontaneous hypertension, we utilized the 
Okamoto-Aoki SHR in a unique breeding paradigm to isolate nuclear and 
mitochondrial genes responsible for the manifestation of heritable hypertension.   
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2.2 Development of BN/SHR-mtSHR “conplastic” rat model for investigating 
physiological and genetic mechanisms of spontaneous hypertension 
 
Hypertension in the Okamoto-Aoki SHR is both neurogenic and genetic in nature.  
The present study measured the arterial blood pressures of offspring over six 
generations (F1-BC5) of breeding in a “conplastic” colony derived from mating a 
female hypertensive, SHR with a systolic arterial pressure (SAP) averaging 188 
mmHg with two normotensive Brown Norway (BN) males (SAP 100 & 104 
mmHg, respectively).  Hypertension was defined in all offspring as a SAP ≥ 
145mmHg, normotension as SAP ≤ 124mmHg and borderline hypertension as 
125mmHg < SAP < 145mmHg.   F1 – BC5 female offspring with a SAP ≥ 
145mmHg were back bred to the original, normotensive, founder BN males 
(Figure 2.1).  Offspring at each generation were raised to adulthood and blood 
pressure measurements were obtained by tail cuff plethysmography at 8, 12, and 
16 weeks of age, as well as into later adulthood ages.  The purpose of this 
breeding paradigm was two-fold.  First, hypertensive nuclear “loci” that are likely 
causal to hypertension were isolated on a normotensive, Brown Norway 
background.  Second, as females were phenotypically selected for back breeding 
at each generation, all offspring of the colony had identical mitochondrial 
genomes of the founder SHR hypertensive female.  This breeding paradigm 
allowed for the investigation of any potential role that the mitochondria may play 
in the development and maintenance of the inherited hypertension.  Six 
generations produced more HT (n=88; 46%) than NT (n=21;11%) offspring, 
documenting consistent and dominant expression of the hypertensive phenotype.  
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These results indicate that dominant alleles of both the nuclear and mitochondrial 
genomes may be responsible for the development of hypertension in rats with a 
decreasing SHR nuclear genome that is replaced with a Brown Norway genome. 
 
2.2.1 Methods and Materials 
 
Rats were raised in a 12 hr light: 12 hr dark cycle in a climate at 20° to 22°C from 
birth.  At 3 weeks of age, rats were weaned and transferred to either individual 
(males) or group (≤3 females of the same litter) solid-wall cages with bedding 
and were provided a commercial standard rodent chow and tap water ad libitum.  
Beginning at 10 weeks of age, rats were phenotyped as normotensive, borderline 
hypertensive or hypertensive using tail cuff plethysmography (Kent Scientific, 
Torrington, CT).  Hypertensive female offspring were then back-crossed to the 
original progenitor BN males for 5 subsequent generations.  All rats in the colony 
possessed identical mitochondrial genomes, with increasing BN nuclear genome 
with each subsequent backcross generation.  After repeated blood pressure 
recordings that assured consistent determination of adult arterial pressure, rats 
were euthanized with an overdose of sodium pentobarbital (60 mg/kg i.p)., 
immediately decapitated, and organ tissues were rapidly frozen in a solution of 
dry ice and acetone.   
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2.2.2 Measurement of arterial pressure.  
 
Since animals were to be back-bred to the founder males in the establishment of 
the conplastic genome, tail cuff plethysmography was used as a phenotyping 
methodology only to establish basic individual blood pressures. To minimize 
stress and improve reliability of blood pressure measurements, several steps 
were used in the blood pressure recording method that has been previously 
characterized and published (Kurtz, Griffin et al. 2005).  Rats were exposed and 
acclimated to the measurement procedures and restraint equipment prior to BP 
recordings.  A dark cover was placed over the restrained animal for the duration 
of the BP measurement, and BP recordings were performed at the same time 
each day.  All equipment was thoroughly cleaned and disinfected before and 
after each individual rat to eliminate foreign scent.  Animals were moderately 
warmed to dilate the ventral artery.  Arterial pressures were derived from the 
average results of ≥5 measurements in each recording session.  The average 
blood pressures of ≥5mmHg separate recording sessions with <5% variability 
were used to establish the phenotype of each animal.  Both systolic and diastolic 
pressures were obtained and recorded.  For purposes of reporting, the systolic 
pressures were used for the determination of the specific individual phenotype. 
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2.3 Results 
 
Progenitor female SHR had a SAP of 188mmHg and progenitor BN males had 
SAPs of 100 (BN*) and 104 (BN^) mmHg.  The BN*/SHR-mtSHR produced six 
generations, yielding 94 total offspring, with 42.6% (n=40) expressing the 
hypertensive phenotype, 42.6% (n=40) expressing the BHT phenotype, and only 
14.9% (n=14) expressing the normotensive phenotype (Table 2.1). The 
BN^/SHR cross/backcross also produced six generations, yielding 71 total 
offspring, with 52.1% (n=37) expressing the hypertensive phenotype, 39.4% 
(n=28) expressing the BHT phenotype, and only 8.5% (n=7) expressing the 
normotensive phenotype (Table 2.2). Together, the 6 total generations produced 
190 offspring, with 110 (58%) female and 80 (42%) male offspring.  There were 
significantly more hypertensive (n=88; 46%) than normotensive offspring 
(n=21;11%), while a large number of individuals expressed the intermediate 
phenotype (n=81; 43%). There were no differences in SAP between male and 
female offspring at any generation.  Furthermore, comparison of systolic, 
diastolic and mean arterial pressures of male and female offspring across all 
backcross generations did not demonstrate any gender differences in arterial 
pressures. Hypertension was dominantly expressed and maintained across all 
six offspring generations of BN/SHR-mtSHR rats (Figure 2.2).  
 
With the conplastic breeding paradigm, the BN contribution to the nuclear 
genome at each generation is as follows: F1: 50%, BC1: 75%, BC2: 87.5%, BC3: 
93.75%, BC4: 96.875%, BC5: 98.4375%.  Thus, at the 6th generation, SHR only 
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accounts for 1.5625% of the nuclear genome, however, the hypertensive 
phenotype is still dominantly expressed (Figure 2.2).  Additionally, the 
mitochondrial genomes of all offspring (n=190), barring any mutations, are 
identical to the founder SHR female. 
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2.4 Implications and Significance 
 
Because of the lack of appropriate animal models, the potentially causal 
contributions of inherited mitochondrial genomic factors to complex traits are less 
well studied compared with inherited nuclear genomic factors. To evaluate the 
effects of these mtDNA variations in the absence of the corresponding nuclear 
genomic factors as confounding variables, novel conplastic BN/SHR-mtSHR rats 
were constructed using a founder male back breeding paradigm and 
characterized for the existence of hypertension.  Utilizing this unique rodent 
colony, one can begin to understand the different roles that the nuclear and 
mitochondrial genome may be playing in the development of chronic elevated 
arterial pressure, and subsequently the development of cardiovascular disease 
associated with arterial hypertension.   
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Figure 2.1: Breeding paradigm for BN/SHR-mtSHR rats.  Hypertensive 
female SHR (SAP= 188mmg) was crossed with two BN males (100mmHg* 
and 104mmHg^ respectively).  Back-breeding female offspring using 
phenotypic selection of elevated arterial pressure (>145mmHg) was used to 
provide the second generation (BC1).  Subsequent back-crossing was 
performed for five additional generations to create 6 total generations (F1, 
BC1-BC5). 
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Figure 2.2: Six generations of BN/SHR-mtSHR rats with 
corresponding average systolic pressure (SAP) values.  The Po 
generation represents repeated measures of the founding SHR and 
BNs.  Each individual dot in generations F1-BC5 represent average 
BP of individual rats. Three distinct populations persisted throughout 
all 6 generations (NT animals above red dotted line, NT animals 
below green dotted line, and BHT animals between red and green 
dotted lines), with hypertension being dominantly expressed and 
maintained.  Modified from (Collett, Hart et al. 2013) 
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Table 2.1: Phenotypic characterization of BN*/SHR-mtSHR colony.  Phenotypes 
are separated according to gender.  There was no difference in SAP between 
genders.  SAP values are expressed as mean ± S.E.M.   
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Table 2.2: Phenotypic characterization of BN^/SHR-mtSHR colony.  Phenotypes 
are separated according to gender.  There was no difference in SAPs between 
genderss.  SAP values are expressed as mean ± S.E.M  
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3.1 Introduction 
 
Hypertension and the chronic elevation of blood pressure constitute a primary 
and significant factor in the development of cardiovascular disease.  Essential 
hypertension is regarded as a multi-factorial disease, influenced by both genetic 
makeup and environmental conditions that can alter genomic expression 
(National Heart, Institute et al. 1977), (Raizada, Sumners et al. 1993), (Schork, 
Krieger et al. 1995).  The polygenic nature of hypertension and its dependence 
on environmental factors complicate the clear identification of genetic factors that 
directly increase blood pressure (Joe and Garrett 2005).    The rat is a well-
established animal model for investigating human hypertension, with over 25,000 
papers reported on hypertension in rats alone (Kwitek-Black and Jacob 2001).   
Rat models of spontaneous hypertension, in particular, the SHR, have been 
critical to our understanding of blood pressure control and the pathophysiology of 
hypertension.  Significant progress has been made to map the genes involved in 
blood pressure regulation in these animal models.  Nuclear and mitochondrial 
genome scans have been carried out in rats, mice and humans and have 
revealed several potential genomic regions that may contain genes involved in 
the pathogenesis of spontaneous hypertension (Rapp 2000).  Molecular genetic 
analysis proves that BP regulation is polygenic, and there is good evidence for 
several BP related quantitative trait loci (QTLs) on nearly every rat chromosome 
(Deng, Dene et al. 1994), (Doris 2002), (Hilbert, Lindpaintner et al. 1991), 
(Hopkins and Hunt 2003), (Rapp, Dene et al. 1994), (Schork, Krieger et al. 1995).  
Linkage analyses of populations derived from the SHR shows potential BP QTLs 
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at numerous loci, however, the precise nature of the genetic mechanisms 
underlying essential hypertension remains unanswered.  
 
Significant data from our lab and others have documented that angiotensin II and 
the renin-angiotensin system play a critical role in maintenance of arterial blood 
pressure and that this hormonal system is elevated in several experimental 
models of hypertension, as well as human essential hypertension (Cowley 1992), 
(de Gasparo, Catt et al. 2000), (Doris 2002), (Lenkei, Palkovits et al. 1997), 
(Lifton, Gharavi et al. 2001), (Reinhart, Lohmeier et al. 1995), (Weir and Dzau 
1999).   It has been suggested that the renin-angiotensin system RAS plays a 
pathogenic role in the development of hypertension in Aoki-Okamoto SHR.  An 
elevated RAS impacts blood pressure directly via vasoconstriction and sodium 
retention, as well as indirectly, through increased reactive oxygen species, 
altering redox signaling and increased sympathetic outflow.   
Here we demonstrate a unique rat colony developed by breeding a hypertensive 
female Okamoto-Aoki SHR with male, normotensive Brown Norway (BN) rats.  
Hypertensive female offspring were backcrossed with the original males for 5 
subsequent generations.  Despite the dilution of the “hypertensive” nuclear 
genome, hypertensive phenotype expressed by the founder female was 
dominantly expressed and maintained across 6 generations of BN/SHR-mtSHR 
rats.  All progeny however, have identical mitochondrial genomes.  We 
investigated the tissue-specific mRNA expression of the RAS pathway, including 
angiotensinogen (AGT), renin (REN), angiotensin converting enzyme 1 (ACE1), 
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angiotensin converting enzyme 2 (ACE2) and angiotensin II, type 1 receptors 
(Agtr1a) in normotensive and hypertensive BN/SHR-mtSHR backcross rats.  It is 
hypothesized that tissue-specific increased RAS expression contributes to 
heritable hypertension in BN/SHR-mtSHR rats. 
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3.2 Materials and Methods 
 
3.2.1 Animals.  
 
All experiments were carried out in accordance with the AAALAC Guide to the 
Care and Use of Laboratory Animals and all protocols were previously approved 
by the University of Kentucky Institutional Animal Care and Use Committee (UK 
IACUC).  A congenic colony using phenotypic selection was employed.  The 
Aoki-Okamoto SHR/Brown Norway (BN/SHR-mtSHR) rat colony was developed by 
breeding a female SHR (Charles River Labs, Wilmington, MA) with 2 different 
normotensive Brown Norway males (BN* and BN^, respectively; Charles River 
Labs, Wilmington, MA).  Rats were raised in a 12 hr light: 12 hr dark cycle in a 
climate at 20° to 22°C from birth.  At 3 weeks of age, rats were weaned and 
transferred to either individual (males) or group (≤3 females of the same litter) 
solid-wall cages with bedding and were provided a commercial standard rodent 
chow and tap water ad libitum.  Beginning at 10 weeks of age, rats were 
phenotyped as normotensive, borderline hypertensive or hypertensive using tail 
cuff plethysmography (Kent Scientific, Torrington, CT).  Hypertensive female 
offspring were then back-crossed to the original progenitor BN males for 5 
subsequent generations.  All rats in the colony possessed identical mitochondrial 
genomes, with increasing BN nuclear genome with each subsequent backcross 
generation.  After repeated blood pressure recordings that assured consistent 
determination of adult arterial pressure, rats were euthanized with an overdose of 
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sodium pentobarbital (60 mg/kg i.p)., immediately decapitated, and organ tissues 
were rapidly frozen in a solution of dry ice and acetone.   
Brains were carefully removed from the skull, and hypothalami were excised 
using previously characterized specific landmarks:  anterior – optic chiasm; 
lateral – optic nerve projections; dorsal – fornix. 
Age and sex matched HT (N=20) and NT (N=20) animals across 6 generations of 
BN/SHR-mtSHR were chosen for RAS mRNA evaluation.  Animals in the 
backcross generation 3 (BC3) were chosen for protein analysis as there were an 
appropriate number of age and sex matched NT and HT rats within a single 
generation. 
 
3.2.2 Measurement of Arterial pressure.  
 
Systolic arterial pressure (SAP) was evaluated in parents and offspring beginning 
at 10-12 weeks of age.  Phenotypes were assigned as either normotensive (NT: 
SAP ≤ 124mmHg), borderline hypertensive (BHT:  125 ≤ SAP < 145 mmHg) or 
hypertensive (HT: SAP ≥ 145mmHg).  Since animals were to be back-bred to the 
founder males in the establishment of the conplastic genome, tail cuff 
plethysmography was used as a phenotyping methodology only to establish 
basic individual blood pressures. To minimize stress and improve reliability of 
blood pressure measurements, several steps were used in the blood pressure 
recording method that has been previously characterized and published (Kurtz, 
Griffin et al. 2005).  Rats were exposed and acclimated to the measurement 
procedures and restraint equipment prior to BP recordings.  A dark cover was 
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placed over the restrained animal for the duration of the BP measurement, and 
BP recordings were performed at the same time each day.  All equipment was 
thoroughly cleaned and disinfected before and after each individual rat to 
eliminate foreign scent.  Animals were moderately warmed to dilate the ventral 
artery.  Arterial pressures was derived from the average results of ≥5 
measurements in each recording session.  The average blood pressures of 
≥5mmHg separate recording sessions with <5% variability were used to establish 
the phenotype of each animal.  Both systolic and diastolic pressures were 
obtained and recorded.  For purposes of reporting, the systolic pressures were 
used for the determination of the specific individual phenotype. 
 
3.2.3 RNA Extraction and RT-PCR.   
 
Kidney, liver and lung tissue were harvested from HT and NT rats (n=20 NT; 
n=20 HT) as described above.  Total RNA was extracted by Trizol reagent 
(Invitrogen, Carlsbad, CA) and purified using RNeasy minicolumns (Qiagen Inc., 
Valencia, CA) according to manufacturer’s protocol.  Possible genomic DNA in 
total RNAs was digested with RNA-free DNase I (Qiagen Inc., Valencia, CA).  
Concentration and purity of all RNA samples was determined by the Nanodrop 
ND-1000 spectrophotometer (Nanodrop Technologies, Wilmington, DE).  
Extracted RNA was reverse-transcribed into complementary DNA (cDNA) using 
qScript cDNA supermix (Quanta Biosciences, Gaithersburg, MD) in a total 
volume of 20µl using a MyCyler Thermal Cycler (Bio-Rad Laboratories, Hercules, 
CA).  
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3.2.4 Quantitative Real-Time PCR.   
 
Quantitative Real-Time PCR was performed on a StepOnePlus Real-time PCR 
system (Applied Biosystems).  Real-time quantitative PCR amplifications were 
performed in triplicate in a 96-well plate.  For normalization, GAPDH was used as 
the reference gene.  Pre-designed primers and hydrolysis probes were 
purchased from Integrated DNA Technologies, Inc.  (Agtr1a; Primer 1: 5’-
CCAGCCATTTTATACCAATCTC-3’, Primer 2: 5’-TCCTGTTCCACCCGATCA-3’, 
Probe: 5’-/HEX/CAGCTCTGC/ZEN/CACATTCCCTGAGT/ 3IABkFQ/-3’.) 
(GAPDH; Primer 1: 5’GTAACCAGGCGTCCGATAC-3’, Primer 2: 5’-
GTTCTAGAGACAGCCGCATC-3’, Probe: 5’-/56-FAM/ATCCGTTCA/ZEN/ 
CACCGACCTTCACC/3IABkFQ/-3’.)  Pre-designed TaqMan primers and 
hydrolysis probes for AGT (Rn00593114_m1), REN (Rn00561847_m1), ACE1 
(Rn00561094_m1), ACE2 (Rn01416293_m1) were purchased from Life 
Technologies.   Relative gene expression was calculated using the comparative 
CT method.  Primers and probes were verified and operating at similar 
efficiencies. 
 
 
3.2.5 Membrane Protein Extraction.  
 
Whole kidney and hypothalamic tissues were placed in an ice-cold buffer solution 
containing 1M Tris, 5M NaCl, 0.5M EDTA, 100% Brij 96/97 and 10% NP40 with 
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0.3% protease inhibitor leupeptin (50μM), aprotinin (50nM) and pepstatin (1μM).  
Tissue samples were immediately homogenized (PowerGen® 125 Homogenizer, 
Fisher Scientific, Pittsburgh, PA) at 4°C for approximately 15 seconds.  After 
complete homogenation, samples were loaded into a centrifuge (Heraeus 
Biofuge 13, Baxter Scientific, Deerfield, IL) and spun at 13,000 rpm for 10 
minutes at 4°C.  Protein concentration was determined for each sample using 
colorimetric assay according to Lowry et al. (Lowry, Rosebrough et al. 1951). 
 
3.2.6 Western blot analysis of AT1 Receptor.  
 
Kidney and hypothalamic protein samples were electrophoretically separated on 
4% to 10% SDS-Page gels at 150V/50mA for 1 hour.    Separated proteins were 
transferred by electroelution (200V, 1-2hrs) to polyvinylidene difluoride (PVDF) 
membranes (0.45μm;Millipore, Bedford, MA).  Molecular weight markers (~10-
190kDa; Benchmark Prestained Protein Ladder, Invitrogen, Carlsbad, CA) were 
used to estimate molecular mass.  Blots were blocked with 5% bovine serum 
albumin (BSA) in Tris-buffered saline.  Blots were incubated with primary 
antibodies AT1r (1:200, sc-81671) and β-tubulin (loading control; 1:200, sc-
23949; Santa Cruz Biotechnology Inc., Santa Cruz, CA) at 25°C for 2 hours.  
Blots were washed with Tris-buffered saline/0.1% Tween-20 (TBST) and then 
exposed to secondary antibody conjugated to horseradish-peroxidase (1:2000, 
sc-2005; Santa Cruz, CA) at 25°C for 2 hours.  Detection of specific proteins was 
accomplished using enhanced chemiluminescence (SuperSignal West Pico, 
Thermo Scientific, Rockford, IL) according to manufacturer’s instructions, and 
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blots were exposed to BioMax Light Autoradiography film (Kodak #1788207).  
Densitometric results were reported as integrated values (area density of band) 
and expressed as a ratio of AT1r to loading control (β-tubulin).  Results were then 
compared between phenotypic groups.  Lanes lacking protein were subject to 
AT1r and β-tubulin primary antibody to verify antibody selectivity.  Densitometry 
reflects mean ± S.EM. of all samples. 
 
3.2.7 Statistical analysis.  
 
Blood pressures, as well as tissue AT1r protein expression between NT and HT 
BN/SHR-mtSHR rats were analyzed using an Student’s T-test.  Renal AGT, REN, 
ACE1, ACE2 and Agtr1a mRNA expression levels between HT and NT BN/SHR-
mtSHR rats were analyzed using Mann-Whitney U Test comparisons.  The 0.05 
level of probability was utilized as the criterion of significance.  All statistical 
analyses were performed using GraphPad Prism 4 (GraphPad Software, Inc., La 
Jolla, CA).  
 
 
 
 
 
 
 
80 
 
3.3 Results 
 
3.3.1 Arterial pressure phenotyping of  BN/SHR-mtSHR  colony.   
 
Systolic arterial pressure phenotypes were assessed weekly beginning at 10-12 
weeks of age according to the following arterial blood pressure parameters: 
normotensive (NT: SAP ≤ 124mmHg), borderline hypertensive (BHT:  
125mmHg<SAP< 145 mmHg) or hypertensive (HT: SAP > 145mmHg).  
Progenitor female SHR had a SAP of 188mmHg and progenitor BN males had 
SAPs of 105 (BN*) and 103 (BN^) mmHg.  The BN*/SHR-mtSHR cross/backcross 
produced six generations, yielding 94 total offspring, with 42.6% (n=40) 
expressing the hypertensive phenotype, 42.6% (n=40) expressing the BHT 
phenotype, and only 14.9% (n=14) expressing the normotensive phenotype. The 
BN^/SHR-mtSHR cross/backcross also produced six generations, yielding 71 total 
offspring, with 52.1% (n=37) expressing the hypertensive phenotype, 39.4% 
(n=28) expressing the BHT phenotype, and only 8.5% (n=6) expressing the 
normotensive phenotype.  Together, the 6 total generations produced 190 
offspring, with 110 (58%) female and 80 (42%) male offspring.  There were 
significantly more hypertensive (n=88; 46%) than normotensive offspring 
(n=21;11%), while a large number of individuals expressed the intermediate 
phenotype (n=81; 43%). There were no differences in SAP between male and 
female offspring at any generation.  Furthermore, comparison of systolic, 
diastolic and mean arterial pressures of male and female offspring across all 
backcross generations did not demonstrate any gender differences in arterial 
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pressures. Hypertension was dominantly expressed and maintained across all 
six offspring generations of BN/SHR-mtSHR  rats (Figure 3.1).  
 
3.3.2 Renal Agtr1a mRNA expression is higher in hypertensive BN/SHR than in 
normotensive BN/SHR-mtSHR rats.   
 
The mRNA levels of AGT, REN, ACE1 and ACE2 and Agtr1a in renal tissue were 
evaluated NT and HT BC3 (NT: n=6, HT: n=6; Figure 3.2) and in HT and NT rats 
representative of each generation of BN/SHR-mtSHR rats (n=20 NT; n=20 HT; 
Figure 3.3).  Animals exhibiting the most extreme phenotypes were chosen for 
mRNA expression analysis.  AGT, REN, ACE1 and ACE2 mRNA levels were not 
different between NT and HT BN/SHR-mtSHR rats.  Renal Agtr1a was increased 
by ~2.5-fold (P < 0.05) in HT compared to NT BN/SHR-mtSHR rats (Figure 3.2).  
Expression is reported as relative expression using 2-ΔΔCT method.   NT values 
were normalized to 1.    
 
3.3.3 Systemic RAS mRNA expression is not different in hypertensive compared 
to normotensive BN/SHR-mtSHR rats.  
 
The mRNA levels of liver AGT, Agtr1a and lung ACE1 were evaluated in HT and 
NT BN/SHR-mtSHR rats (n=20 NT; n=20 HT).  Animals exhibiting the most 
extreme phenotypes were chosen for mRNA expression analysis.  Liver AGT, 
Atgr1a and lung ACE1 mRNA levels were not different between NT and HT 
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BN/SHR-mtSHR rats (Figure 3.4 A,B,C).  Expression is reported as relative 
expression using 2-ΔΔCT method.   NT values were normalized to 1.    
 
3.3.4 Renal AT1 receptor protein expression is higher in hypertensive BN/SHR-
mtSHR than in normotensive BN/SHR-mtSHR rats.  
 
Western blot analysis of AT1 receptor protein from whole kidney homogenates 
using the monoclonal antibody showed that AT1 receptor protein levels were 
significantly higher (p<0.05; Figure 3.5A) in BC3 HT rats compared to NT rats.  
The ratio of renal AT1 to β-tubulin densitometric signals were 1.000 ± 0.097  vs. 
1.379 ± 0.06975 (Figure 3.5B).  Regression analysis was also performed, 
indicating a positive correlation (r2=0.6502, p<0.05) between SAP and AT1 
receptor protein expression in kidney of BC3 BN/SHR-mtSHR rats (Figure 3.5C). 
 
3.3.5 Hypothalamic AT1 receptor expression is higher in hypertensive BN/SHR-
mtSHR than in normotensive BN/SHR-mtSHR rats.  
 
Western blot analysis of AT1 receptor protein from hypothalamus homogenates 
using the same monoclonal antibody showed that AT1 receptor protein levels 
were significantly higher (p<0.05) in BC3 HT rats compared to NT rats (Figure 
3.6A).  The ratio of hypothalamic AT1 to β-tubulin was 2.600 ± 0.07616 (NT: 
N=16) vs. 3.072 ± 0.2031 (HT: N=18) respectively (Figure 3.6B).  Regression 
analysis was also performed, indicating a positive correlation (r2=0.4781, p<0.05) 
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between SAP and AT1 receptor protein expression in hypothalamus of BC3 
BN/SHR-mtSHR rats (Figure 3.6C).  
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3.4 Discussion 
 
The main findings of this study are: 1) elevated arterial pressure is dominant and 
maintained across 6 generations of BN/SHR-mtSHR rats, despite the increasing 
nuclear genomic contribution of the NT male donor rats, 2) hypertensive 
BN/SHR-mtSHR rats across 6 generations exhibit elevated renal Agtr1a mRNA 
expression compared to NT BN/SHR-mtSHR rats, while expression of renal REN, 
liver AGT and Agtr1a and lung ACE1 were not different 3) hypertensive BN/SHR-
mtSHR in the BC3 generation exhibit an elevated AT1r protein expression in 
kidney and hypothalamus compared to NT BN/SHR-mtSHR rats, 4) increased AT1r 
expression is positively correlated with elevated SAP in BC3 BN/SHR-mtSHR rats.  
Taken together, these results suggest that hypertension is dominant in the 
presence of increasing normotenive “loci” and that tissue-specific altered 
expression of AT1r, but not other aspects of renal or systemic RAS, may underlie 
heritable hypertension. 
 
The SHR has been the most widely studied genetic model of essential 
hypertension in the past four decades (Pinto, Paul et al. 1998).  Neurogenic in 
nature, the underlying mechanisms of the onset and manifestation of 
hypertension in the SHR remains to be fully elucidated.  In this experimental 
paradigm, an attempt to isolate genomic regions from which hypertension derives 
in a “conplastic” colony using phenotypic selection was employed.  In these rats, 
the nuclear genome of the 6th generation (BC5) offspring is comprised of ~96.9% 
original BN males, and only 1.6% of original donor SHR.    The dilution of the 
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hypertensive genome had seemingly little effect on the manifestation of the 
hypertensive phenotype from generation F1 through backcross 5 (Figure 3.1).   It 
is clear, however, that the magnitude of the hypertension was never as high in 
the offspring, as in the progenitor SHR even from the initial F1 generation.  In 
fact, there is approximately a 30 mmHg difference between the average SAP of 
the SHR and F1 generation offspring. However, from the F1 generation forward, 
the magnitude of elevated blood pressure did not decline toward the BN blood 
pressure in any of the subsequent offspring generations.  Thus, although a 
significantly increasing influence of the BN genome is transmitted following 
genetic mixing with SHR of subsequent backcross generations, the impact of the 
SHR genome was fully maintained for 6 consecutive generations (F1-BC5) 
following the initial mating. 
 
Since the discovery of “renin” in 1898 and subsequent recognition that Ang II is 
pressor, the RAS has been extensively studied and remains a major candidate 
as a causative factor in elevated arterial pressure and the pathogenesis of 
hypertension (Carey and Siragy 2003), (de Gasparo, Catt et al. 2000), 
(Tigerstedt and Bergman 1898).  The angiotensin II, type 1 receptor has been 
extensively evaluated in rodents and has subsequently become a target as a 
causal factor in the development of essential hypertension.  Reja et al. (2006) 
showed that gene expression levels of AT1r, extracellular signal-regulated kinase 
2 and phosphatidylinositol 3-kinase were significantly higher in the PVN, RVLM 
and adrenal medulla in SHR compared to normotensive WKY rats. Raizada et al. 
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(1993) showed that AT1r mRNA was higher in the brains of the SHR compared to 
normotensive WKY rats.  Furthermore, Gyurko et al. (1993) showed that 
antisense inhibition of AT1 receptor mRNA in the brain reduces the magnitude of 
hypertension in adult SHR.  Data from our study supports the notion that 
elevated AT1 receptors may play a role in SHR-derived elevated arterial 
pressure.  Hypertensive BN/SHR-mtSHR rats across several generations exhibit 
elevated renal specific Agtr1a mRNA (Figures 3.2 and 3.3) expression while 
expression of other renal RAS components, as well as liver AGT and lung ACE1 
were not different (Figure 3.4).  In the BC3 generation, where the nuclear 
genome of the original SHR accounts for only ~6.2%, HT rats had significantly 
higher AT1r and protein expression than normotensive rats in kidney and 
hypothalamic tissue (Figure 3.5 and 3.6).  Furthermore, average SAP and tissue 
expression of AT1r were positively correlated (Figure 3.5C and 3.6C), indicating 
that tissue specific expression of AT1r expression may critically impact the 
development and maintenance of SHR hypertension.  Increased AT1r protein 
could potentially have drastic effects on the cardiovascular system, including the 
pathogenesis of hypertension, and seems to play a role in the development of 
hypertension in BN/SHR-mtSHR rats.  Ang II’s effect in the kidney would be 
exacerbated, increasing proximal tubular sodium reabsorption and decreasing 
renal blood flow.    In the hypothalamus, elevated AT1r expression could increase 
sympathetic nervous activity and/or vasopressin secretion, subsequently 
increasing vascular resistance and sodium and water retention.  The 
hypothalamus is of particular interest, as it plays a major role in sympathetic 
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outflow, vasopressin production and osmoregulation (Scherrer 1959).  Recently, 
commercially available AT1r antibodies have come under scrutiny for lack of 
specificity, and therefore may lead to erroneous results (Herrera, Sparks et al. 
2013).  It is critical to note here, however, that the antibody used for this study 
has not previously been identified as non-specific, and that our mRNA 
expression data fully corroborates the protein data that AT1r expression is 
elevated in kidney of BN/SHR-mtSHR backcross rats.  
 
With the abundance of knowledge on the role of both circulating and tissue RAS 
in BP control, it is hypothesized that genetic variability in one or more of the RAS 
components could account for the pathogenesis of hypertension. Common 
variants of the RAS genes, including those coding for angiotensinogen and 
angiotensin-converting enzyme were some of the first to be associated with 
altered blood pressure control (Norton, Brooksbank et al. 2010).  Several linkage 
analysis and genome wide association studies have been performed in both 
rodents and humans in regards to RAS genes, producing variable results (Baudin 
2002), (Bonnardeaux, Davies et al. 1994), (Jeunemaitre, Soubrier et al. 1992), 
(Kainulainen, Perola et al. 1999), (Rigat, Hubert et al. 1990), (Rothermund and 
Paul 1998), (Schmidt, Beige et al. 1997), (Tomino, Makita et al. 1999), (Zhu, 
McKenzie et al. 2000).  Results from our current study highlight a renal-specific 
elevation of a single gene of the RAS, therefore indicating genomic 
polymorphisms at this allele are not causal to the manifestation of the disease.  
Gene expression and subsequent protein synthesis may be equally, if not more 
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important than heritable nucleotide differences in elucidating the causes of 
complex, multigenic diseases.  Data from this study indicate that AT1r mRNA and 
receptor protein expression may have a significantly more important role than 
other aspects of RAS in heritable hypertension.   
 
Due to the breeding paradigm (i.e. backcrossing hypertensive females with 
founder males), the influence of the mitochondrial genome (female transmission) 
on the pathophysiology of hypertension should be taken into consideration. 
These results provide strong evidence for the dominance of loci within the SHR 
genome that are highly resistant to increasing normotensive influence of the BN 
genome.  At present, there are few data that identify the specific genes located in 
these “SHR dominant” regions.  However, it is likely that these genomic regions 
contain numerous blood pressure controlling gene loci (Rapp 2000), (Lowry, 
Rosebrough et al. 1951), (Kaschina and Unger 2003).  As hypertensive females 
were phenotypically selected for backcross, all offspring (F1, BC2-BC5) should 
have identical mitochondrial genomes, barring any mutation(s).  Mitochondrial 
dysfunction has recently been implicated in a wide variety of genetic disorders 
(Taylor and Turnbull 2005), (Wallace 1999).  Alterations in mitochondrial function 
are observed in conjunction with the development of hypertension in rodents and 
humans (Chan, Wu et al. 2009), (Kumarasamy, Gopalakrishnan et al. 2010), 
(Pravenec, Hyakukoku et al. 2007).  The genetic association of mtDNA variants 
(Kumarasamy, Gopalakrishnan et al. 2010), (Wilson, Hariri et al. 2004) and tRNA 
mutations (Kumarasamy, Gopalakrishnan et al. 2010), (Benigni, Corna et al. 
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2009), (Liu, Li et al. 2009), (Pravenec, Hyakukoku et al. 2007) to type 2 diabetes 
and hypertension directly implicated mitochondrial defects to the etiology of 
cardiovascular disease and metabolic syndrome.  Mitochondrial integrity and 
potential dysfunction is currently being evaluated in the BN/SHR-mtSHR rats. 
 
A potentially critical avenue in investigating the underlying mechanisms of 
heritable hypertension in BN/SHR-mtSHR is the relationship between the renin-
angiotensin system and mitochondrial dysfunction.  The role played by 
angiotensin II in developing mitochondriopathy has been advanced recently by 
Benigni et al. (2009)   Deletion of the Agtr1a gene resulted in the reduced age-
related cardio-renal complications, improved mitochondrial biogenesis, and 
increased longevity in mice.  Additionally, treatment with antioxidants, 
mitochondrial superoxide dismutase mimetics, and AT1r blockers decreased 
vascular O2- production and attenuated development of hypertension in SHR 
(Park, Touyz et al. 2002), (Rodriguez-Iturbe, Zhan et al. 2003), (Shokoji, 
Nishiyama et al. 2003).  De Cavanagh et al. (2006) have demonstrated that 
oxidative stress is associated with mitochondrial dysfunction in SHR, and that 
this dysfunction is attenuated with AT1r blockade with losartan.   Taken together, 
there is significant evidence of mtDNA mutations and/or altered mitochondrial 
genetic expression is influenced, at least in part, by the RAS, and that this 
relationship may play a significant role in the development of hypertension. 
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In summary, the present results indicate that hypertension is dominantly 
expressed in BN/SHR-mtSHR rats, and that elevated arterial pressure is positively 
correlated with the upregulation of kidney AT1r mRNA, as well as kidney and 
hypothalamic AT1r protein expression, while other aspects of the local and 
systemic RAS pathways are not different.  It has been reported that AT1r mRNA 
is regulated in a tissue-specific manner that is distinct among the other 
components of the RAS, and potentially independent of changes in circulating 
Ang II (Sechi, Griffin et al. 1996). Our current study supports this finding, as well 
as adds insight into the heritability and expression of different aspects of RAS.  
The maintenance of hypertension under conditions where the proportion of the 
female progenitor SHR mitochondrial genome remains intact, nuclear genome is 
continually reduced by increasing amounts of normotensive progenitor BN 
genome strongly suggests a major linkage of the SHR genes to the development 
of hypertension.  While the origins of this SHR derived hypertension remain 
unknown, strong physiological evidence for a major neurogenic and RAS 
components have been reported.  Given that the maintenance of hypertension in 
the F1 and subsequent backcross generations, the encoding and linkage of 
hypertensive loci may be directly related to genomic components of the female 
SHR mitochondrial genome.   
 
The presence and abundance of AT1r in the kidney and hypothalamus appears 
to be related to the propagation of the HT phenotype in BN/SHR-mtSHR.  This 
work adds to the body of evidence that quantitative variations in gene expression 
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at loci encoding components of the renin-angiotensin-aldosterone system may be 
genetically linked to or associated with physiological alterations in blood 
pressure.  Though the RAS pathway has been a major therapeutic target for 
decades, understanding the heritability of expression of these targets can help 
switch the focus from treatment to prevention.  The role of AT1 receptors in 
individual tissues and their differential expression provides valuable information 
on how personalized therapy can be used to better treat or prevent 
cardiovascular disease in the future.   
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Figure 3.1: Six generations of BN/SHR-mtSHR rats with 
corresponding average systolic pressure (SAP) values.  Three 
distinct populations persisted throughout all 6 generations, with 
hypertension being dominantly expressed and maintained despite the 
reduction of the SHR nuclear genome.  HT animals used are 
indicated by the red circle.  NT animals used are indicated by the 
blue circle. 
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Figure 3.2: Quantitative Real-Time PCR of renal AGT, 
REN, ACE1, ACE2 and Agtr1a in age and sex 
matched BC3 HT and NT rats.   Data were normalized 
to GAPDH RNA from same samples (NT n=20; HT 
n=20).  There was no difference in AGT, REN, ACE1 
and ACE2 expression HT BC3 rats compared to NT 
BC3 rats.  Agtr1a mRNA levels were ~5X higher in HT 
rats compared to NT rats. 
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Figure 3.3: Quantitative Real-Time PCR of renal AGT, REN, 
ACE1, ACE2 and Agtr1a in age and sex matched HT and NT 
rats representative of all generations in the colony.   Data 
were normalized to GAPDH RNA from same samples (NT 
n=20; HT n=20).  There was no difference in AGT, REN, 
ACE1 and ACE2 expression  in HT compared to NT rats.  
Agtr1a mRNA levels were ~2.5X higher in HT rats compared 
to NT rats. 
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Figure 3.4: Quantitative Real-Time PCR of liver AGT (Figure 
3.4A), lung ACE1 (Figure 3.4B) and liver Agtr1a (Figure 3.4C  
in BC3 HT and NT rats.  Data were normalized to GAPDH RNA 
from same samples (NT n=6; HT n=5).  There was no 
difference in liver AGT, lung ACE1 or liver Agtr1a mRNA 
expression in HT BC3 rats compared to NT BC3 rats.   
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Figure 3.5: Semiquantitative immunoblotting of whole kidney 
tissue homogenates of BC3 HT and NT rats. A: Representative 
blot of AT1r and β-tubulin.  B: Illustrates quantified densitometry of 
hypothalamic AT1r protein.  HT rats exhibited significantly higher 
AT1r protein expression compared to NT rats (p<0.05). C: 
Regression analysis between SAP and AT1r protein expression in 
hypothalamic homogenates.  Average SAP and AT1r protein 
expression were positively correlated (r2=0.6502, * = P<0.05). 
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Figure 3.6: Semiquantitative immunoblotting  of AT1 receptor protein 
from hypothalamus homogenates of BC3 rats. A: Representative blot 
comparing NT, BHT and HT AT1r densities.  Β-tubulin was used as 
housekeeping protein. B: Illustrates quantified densitometry of 
hypothalamic AT1r protein.  HT rats exhibited significantly higher AT1r 
protein expression compared to NT rats (p<0.05). C: Regression 
analysis between SAP and AT1r protein expression in hypothalamic 
homogenates.  Average SAP and AT1r protein expression were 
positively correlated (r2=0.4781, * = P<0.05). 
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CHAPTER 4 
SODIUM BALANCE AND RENAL FUNCTION IN BN/SHR-mtSHR RATS 
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4.1 Introduction 
 
The relationship between dietary NaCl intake and the development of 
hypertension has been the subject of much debate for several decades (Dahl 
1961; MacGregor 1985; Osborn and Camara 1997).  In societies where salt 
intake is less than 50 to 100 mmol/d, hypertension and cardiovascular disease 
(CVD) are rare, and the frequency of hypertension and CVD increase at higher 
levels of salt intake (Weinberger 1996).  Pharmacological therapy with natriuretic 
agents has been very successful, and is still  considered a first line therapy in the 
treatment of hypertension (Weinberger 1996).  However, epidemiological 
observations have established profound heterogeneity between salt intake and 
hypertension.  There is evidence that genetic factors, particularly alterations in 
genes of known osmoregulatory roles, play a very significant role in the 
deleterious impact of hypertension on the progression of renal disease (Rostand, 
Kirk et al. 1982). For instance, the risk of developing end-stage renal disease is 
10- to 20-fold greater in black Americans than in Caucasian American patients 
with essential hypertension, and this increased risk cannot readily be explained 
by differences in the severity or treatment of hypertension (Rostand, Kirk et al. 
1982).  One major difference is salt sensitivity.  Greater sodium retention is 
thought to underlie BP determining physiology of blacks, and though the renin-
angiotensin system has been implicated, the exact mechanisms are currently 
unknown (Tu, Eckert et al. 2014).  The renin–angiotensin system, for example, is 
more likely to be suppressed in blacks than in whites, consistent with greater 
volume expansion from sodium accumulation and water retention (HELMER and 
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JUDSON 1968; Wilson, Bayer et al. 1999).  In addition, BP in blacks in contrast 
to BP in whites typically increases in response to an increase in sodium intake, 
i.e. greater NaCl sensitivity (Weinberger 1996).  Whether blacks have a unique 
renal physiology that puts them at risk for a more aggressive form of 
hypertension is unclear.  What is clear, is that NaCl sensitivity, or possibly the 
inability to “sense” NaCl intake can have a profound effect on arterial pressure, 
the pressure-diuresis-natriuresis relationship and subsequent development of 
hypertension.  Like humans, genetically similar rodent models responding 
differently to NaCl intake have been established.  The SHR parallels the most 
common form of idiopathic hypertension and that of most Caucasian Americans, 
in that most SHR strains are not salt sensitive.  Studies by Lundin et al. (1982) as 
well as Greenberg and Osborn (1994) have shown that renal retention of sodium 
in water should not be of pathogenic importance in identifying causes of 
hypertension in the SHR.  Still, hyperosmotic saline, as well as Ang II injected 
ICV in the SHR and other rodents alters renal sodium handling and increases 
BP, which may be mediated by the activation of renal sympathetic nerve activity 
(Osborn and Camara 1997; Guadagnini and Gontijo 2006).   
 
To further understand the mechanisms of sodium sensing and potential altered 
renal sodium handling in rats stemming from the SHR, we utilized our unique 
conplastic rodent model to evaluate acute renal responses to altered NaCl 
concentrations, when rats were able to titrate their own sodium load.  It is 
hypothesized that hypertensive BN/SHR-mtSHR will be unable to appropriately 
 
 
102 
 
“sense” sodium load, hence ingesting more NaCl, and potentially alter renal 
sodium handling compared with NT BN/SHR-mtSHR. 
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4.2 Methods and Materials 
 
4.2.1 Animals  
 
Male rats generated from sibling-sibling crosses of a BC5 generation from the 
BN/SHR-mtSHR colony described in detail previously were used for the acute 
sodium intake aspect of the experiment.  All animals were maintained in 
temperature controlled rooms with 12:12 h-light/dark cycle.  Rats were raised 
from weaning on normal NaCl chow (0.8% NaCl; Dyets, Bethlehem, PA) and 
given water ad libitum.   Care of the rats before and during experimental 
procedures was conducted in accordance with the policies of the National 
Institutes of Health guidelines for the care and use of laboratory animals. All 
protocols had received prior approval by the Institutional Animal Care and Use 
Committee at the University of Kentucky. 
 
4.2.2 Experimental Protocols 
 
Twelve week old male rats weighing 300-400g were chosen for the experiment.  
Rats were housed in metabolic pens and allowed distilled water and NaCl-free 
chow ad libitum for the entirety of the 17-day experiment.  Rats titrated Na+ intake 
by drinking 0.9% saline for 2 acclimation days, followed by 5 experimental days.  
On the fifth day, BP was measured and rats were then switched to 2.0% 
hypertonic saline for 5 experimental days.  On day 10, BP was measured and 
rats were switched back to 0.9% saline for 5 experimental days (Figure 4.1A).   
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4.2.3 Measurement of Arterial Pressure 
 
Rats previously phenotyped as normotensive (NT: SAP ≤ 124mmHg; n=6) or 
hypertensive (HT: SAP ≥ 145mmHg; n=6) were utilized for this study.  Since 
animals were to be back-bred to the founder males in the establishment of the 
conplastic genome, tail cuff plethysmography was used as a phenotyping 
methodology only to establish basic individual blood pressures. To minimize 
stress and improve reliability of blood pressure measurements, several steps 
were used in the blood pressure recording method that has been previously 
characterized and published (Kurtz, Griffin et al. 2005).  Rats were exposed and 
acclimated to the measurement procedures and restraint equipment prior to BP 
recordings.  A dark cover was placed over the restrained animal for the duration 
of the BP measurement, and BP recordings were performed at the same time 
each day.  All equipment was thoroughly cleaned and disinfected before and 
after each individual rat to eliminate foreign scent.  Animals were moderately 
warmed to dilate the ventral artery.  Arterial pressures were derived from the 
average results of ≥5 measurements in each recording session.  Both systolic 
and diastolic pressures were obtained and recorded.  For purposes of reporting, 
the systolic pressures were used for the determination of the specific individual 
phenotype. 
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4.2.4 Determinations 
 
Sodium and water intake were determined daily by weighing calibrated bottles 
every 24 hours.  Sodium intake was calculated as a product of the volume 
ingested and sodium concentration.  Urine was collected and the volume was 
determined in calibrated cylinders positioned directly under the pens.  Urinary 
sodium concentration was determined by flame photometry, and urinary sodium 
excretion was calculated from the product of urine flow rate and sodium 
concentration.  Sodium balance averaged over the experimental periods was 
determined as the difference between sodium excretion and sodium intake.  
Urinary protein concentration was measured by the method of Lowry et al. 
(1951), and protein excretion was calculated as the product of urine flow rate and 
urinary protein concentration.  Bovine serum albumin was used as the standard. 
 
4.2.5 Statistical analysis  
 
Blood pressures, average sodium intake/excretion, water intake, sodium balance, 
AT1r protein expression and urinary protein between NT and HT BN/SHR-mtSHR 
rats were analyzed using an one-way ANOVA.  Daily sodium intake/excretions 
were analyzed using a two-way ANOVA.  The 0.05 level of probability was 
utilized as the criterion of significance.  All statistical analyses were performed 
using GraphPad Prism 4 (GraphPad Software, Inc., La Jolla, CA).  
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4.3 Results 
 
4.3.1 Arterial pressure did not change during acute sodium challenge.   
 
SAP was significantly higher in the HT BN/SHR-mtSHR (SAP=157.0±5.2 mmHg; 
n=6) compared with NT BN/SHR-mtSHR (SAP=124.2±5.5 mmHg; n=6) to begin 
the study. SAP did not change (p>0.05) during any of the three phases of the 
experiment (Figure 4.1B).   
 
4.3.2 Sodium intake was maintained when offered 2.0% saline in HT while NT 
BN/SHR-mtSHR decreased their sodium intake. 
 
Average daily sodium intake for NT and HT BN/SHR-mtSHR rats is displayed in 
Figure 4.2A.  Average 5-day sodium intake was significantly reduced in NT 
BN/SHR-mtSHR when offered 2.0% hypertonic saline (166.3±21 to 79.554±10 
µEq/day; #p<0.05), which remained suppressed when again offered 0.9% saline 
(69.14±14 µEq/day; #p<0.05; Figure 4.2B).  HT BN/SHR-mtSHR, however, 
maintained sodium intake when offered 2.0% hypertonic saline (127.5±36 to 
147.9±24.9 µEq/day), that was maintained when again offered 0.9% saline 
(89.7±9.8 µEq/day; Figure 4.2B).  HT BN/SHR-mtSHR failed to “sense” hypertonic 
saline challenge, therefore failed to reduce sodium intake (Figure 4.2B).     
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4.3.3 Water intake increased in both HT and NT when offered hypertonic saline. 
 
Average 5-day water intake was significantly increased in NT BN/SHR-mtSHR 
when offered 2.0% hypertonic saline (4.2±0.37 to 11.1±0.628 ml/day; #p<0.05), 
and NT rats maintained an increased water intake when again offered 0.9% 
saline (9.14±0.864 ml/day; #p<0.05; Figure 4.3).  HT BN/SHR-mtSHR also 
increased water intake when offered 2.0% hypertonic saline (5.3±1.0 to 
8.9±0.231 µEq/day; #p<0.05; Figure 4.3), however water intake values were not 
different in HT rats when again offered 0.9% saline (6.4±0.28 ml/day; Figure 
4.3).   
 
4.3.4 Sodium Excretion was higher in HT compared to NT BN/SHR-mtSHR. 
 
Average daily sodium excretion for NT and HT BN/SHR-mtSHR rats is displayed in 
Figure 4.4A.  In accordance with elevated NaCl intake, average 5-day sodium 
excretion was elevated in HT BN/SHR-mtSHR when offered 2.0% hypertonic 
saline (271.7±25.1 to 331.8±31.7 µEq/day), and HT rats maintained an elevated 
sodium excretion when again offered 0.9% saline (313.22±18.1 µEq/day; Figure 
4.4B). NT BN/SHR-mtSHR, however, maintained sodium excretion when offered 
2.0% hypertonic saline (220.5±57.7 to 229.6±52.2 µEq/day), and NT rats 
maintained same sodium excretion when again offered 0.9% saline (191.3±39.4 
µEq/day; Figure 4.4B).  HT rats did, however, excrete more NaCl during the last 
0.9% phase than NT rats (*p<0.05; Figure 4.4B).   
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4.3.5 Sodium Balance was More Negative in HT  BN/SHR-mtSHR. 
 
Cumulative daily sodium balance in illustrated in Figure 4.5A.  HT rats exhibited 
greater variability in maintaining sodium balance during the three experimental 
phases.   Average 5-day sodium balance for NT and HT BN/SHR-mtSHR is 
displayed in Figure 4.5B.  NT averaged (0.9%:-53.6±17.9 µEq/day; 2.0%:-
120.1±8.8 µEq/day; 0.9%: -122.17±7.5 µEq/day; Figure 4.5B) compared to HT 
averages (0.9%: -151.0±29.2  µEq/day; 2.0%: -183.9±18.7 µEq/day; 0.9%: -
226.9±15.5  µEq/day; Figure 4.5B).  HT rats exhibited greater sodium natriuresis 
in all three experimental phases due to elevated arterial pressure (*p<0.05). 
 
4.3.6 Urinary Protein Excretion was Not Different Between NT and HT BN/SHR-
mtSHR. 
 
Urinary protein excretion was maintained and normal in NT and HT BN/SHR-
mtSHR for the entire experimental protocol.  For the three experimental saline 
trials, NT rats averaged (0.9%:476.7±66 µg/day; 2.0%:557.1±71 µg/day; 0.9%: 
441.7±63 µg/day; Figure 4.6) compared to HT averages (0.9%: 328.2±46 
µg/day; 2.0%: 413.3±62 µg/day; 0.9%: 299.7±29 µg/day; Figure 4.6).  Therefore, 
renal function appeared to be normal in NT and HT BN/SHR-mtSHR. 
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4.4 Discussion 
 
The necessity to maintain salt and water balance is an important aspect of land 
dwelling animals.  Alterations in this balance can significantly impact 
cardiovascular health and disease. Epidemiological studies have demonstrated a 
positive correlation between NaCl intake and elevated blood pressure (Grim, Luft 
et al. 1980; Weinberger 1996; Dahl 2005).  Elevated NaCl intake may lead to the 
development of hypertension and cardiovascular complications by signals 
triggered by augmented extracellular [Na+] , extracellular [Cl−] , and/or osmolality 
of extracellular fluids (Orlov and Mongin 2007).  The present study was designed 
to evaluate the influence of acute high NaCl on renal sodium handling and BP in 
rats stemming from the SHR.  This study is unique, in that the experimental 
paradigm allowed rats to titrate their NaCl intake, providing useful information as 
to the rats ability to “sense” sodium load.  Both the kidney and the CNS are 
involved in sodium sensing via at least two different mechanisms: Cl- and Na+ 
sensing in the tubular fluid and plasma osmolality in the CSF.  In the kidneys, 
salt-sensing and the regulation of sodium excretion is provided mainly via TGF.  
TGF is triggered immediately after an elevation of salt concentration in the 
tubular fluid delivered to the JGA and results in the contraction of VSMCs of 
afferent arterioles, thus causing increases in the exposure of proximal tubules to 
high-salt fluid via the attenuation of glomerular capillary pressure and 
GFR.   CNS [Na+] sensors are primarily located in the circumventricular organs, 
separate structures that line brain ventricles and consist of the SFO, MnPO, and 
OVLT (Orlov and Mongin 2007).  In these brain areas, the blood-brain barrier is 
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partially open due to the presence of fenestrated capillaries (Bourque and Oliet 
1997; Hussy, Deleuze et al. 2000). This feature makes the circumventricular 
organs an optimal location for direct sensing of the ionic composition of plasma.  
SFO and OVLT may influence electrical activity of the magnocellular neurons in 
the SON and PVN of the hypothalamus, both of which secrete AVP into the 
circulation (Denton, McKinley et al. 1996; Hussy, Deleuze et al. 2000).  
Vasopressin is produced by the magnocellular neurosecretory cells of the 
hypothalamic SON and PVN, which both project to the median eminence in the 
neurohypophysis.  Such regulation occurs via direct excitatory projections to the 
SON and PVN or indirectly via projections to the MnPO, a nucleus that also 
innervates both the SON and PVN (Hussy, Deleuze et al. 2000).   Interestingly, 
the PVN and SON possess their own intrinsic [NaCl]-sensing mechanism, which 
adds additional complexity to the CNS regulation of salt intake and secretion. 
This mechanism involves sensing changes in CSF osmolality rather than 
alterations in extracellular [Na+] (Mason 1980; Oliet and Bourque 1992).   
 
Leenen and coworkers (Budzikowski, Huang et al. 1998; Huang, Amin et al. 
2006) were the first to propose that blood pressure elevation in animal models of 
hypertension is triggered by augmented NaCl delivery to the CNS.   Elevated 
NaCl diets may significantly affect the regulation of blood pressure and fluid and 
electrolyte balance by way of changes in the sensitivity of the brain to circulating 
or centrally generated humoral factors (Wilson, Bayer et al. 1999; Guadagnini 
and Gontijo 2006).  For example, Andersson showed that hypertonic saline 
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injected into the hypothalamus of the goat induced a large dipsogenic response 
(Andersson, Dallman et al. 1969).  Additionally, when hypertonic saline is 
administered into the CSF of the third ventricle, animals drink more water and 
vasopressin is released from the neurohypophysis (Andersson and Olsson 
1973).   Though HT BN/SHR-mtSHR were able to excrete their increased sodium 
intake, results demonstrate a potential decreased ability to sense sodium load, 
likely via central mechanisms in brain.  Though several mechanisms could be 
involved, we postulate that augmented RAS, in particular, elevated AT1r 
expression may be related to the reduced sodium sensing ability in HT BN/SHR-
mtSHR (Figure 4.7). 
 
It is well documented that endogenous Ang II may contribute to the development 
of certain forms of experimental hypertension, including the SHR.  The 
cardiovascular effects of centrally administered Ang II also may be related to 
NaCl intake.  It has been reported that changes in NaCl intake may be 
accompanied by changes in the density and affinity of Ang II receptors in 
hypothalamic areas of the brain involved in cardiovascular, fluid, and electrolyte 
regulation (Bickerton and Buckley 1961).  Systemic and brain Ang II has been 
shown to participate in blood pressure and salt and water balance through a 
variety of mechanisms including sympathetic outflow, stimulation of vasopressin 
release (Yang, Jin et al. 1992).  Additionally, brain Ang II alters thirst and salt 
appetite, which plays a major role in fluid and electrolyte regulation (Epstein, 
Fitzsimons et al. 1970; Fluharty and Epstein 1983).  Dukacz, et al. (2003) 
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previously demonstrated that long term inhibition of RAS with captopril 
decreased blood pressure in the SHR, resulting in a leftward shift in the 
pressure-natriuresis relationship.  This is significant, as results from our lab 
demonstrate that HT BN/SHR-mtSHR have significantly more hypothalamic AT1r 
protein compared with NT HT BN/SHR-mtSHR, indicating a potential relationship 
between hypothalamic AT1r expression and reduced salt-sensing ability in HT 
BN/SHR-mtSHR (Figure 4.7).  An increase in both gene and protein expression of 
renal AT1r has also been shown in HT BN/SHR-mtSHR (Collett, Hart et al. 2013).  
Taken together, the presence and abundance of AT1r in the hypothalamus or 
kidney is related to the HT phenotype in BN/SHR-mtSHR, and its role may be 
involved in the chronic rightward shift of the renal function curve and/or a 
reduced ability of sodium sensing (Figure 4.7). 
 
The reduced ability to sense salt in HT BN/SHR-mtSHR and the compensatory 
elevation of blood pressure to keep the rats in sodium balance may have 
something to do with activation of renal sympathetic nerve activity.  The elevated 
level of efferent sympathetic tone in the SHR may alter the renal handling of 
sodium and water.  Renal nerve stimulation directly affects both proximal tubular 
sodium reabsorption and renin release (Osborn, Holdaas et al. 1983; Chen and 
Toney 2001).  Greenberg et al. (2000) demonstrated the importance of the renal 
nerves in mediating sodium excretion in response to sodium load in SHRs.  
Camara and Osborn (2005) demonstrated that hypertension induced by chronic 
left ventricular Ang II infusion is dependent upon activation of renal sympathetic 
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nerve activity and is associated with sodium retention.  Furthermore, Camara and 
Osborn  showed that lifelong increases in NaCl intake may sensitize the CNS to 
low doses of Ang II, causing increases in renal sympathetic nerve activity 
mediated by brain AT1r.  Therefore, we postulate that lifetime desensitization of 
orally ingested NaCl causes profound pressure-natriuresis that may be mediated, 
in part, by activation of renal sympathetic nerves and AT1r (Figure 4.7).  
 
In summary, we present data that demonstrate  that HT BN/SHR-mtSHR have a 
reduced ability to sense elevated sodium when given the option to titrate their 
own NaCl load, and this may be related to tissue specific expression of AT1r 
and/or elevated sympathetic nerve activity.  However, it appears that HT 
BN/SHR-mtSHR have normal kidney function and are operating within normal 
kidney natriuresis with increased sodium intake, which agrees with previous 
studies that sodium retention is not of pathogenic importance in the SHR (Lundin, 
Herlitz et al. 1982; Greenberg and Osborn 1994).  It appears then, that the 
elevation of arterial pressure in SHR is important to maintain daily sodium 
balance, i.e., functional pressure-natriuresis.  Hence, HT BN/SHR-mtSHR is truly a 
model of “essential” hypertension.  It is concluded then, that long-term increases 
in arterial pressure are necessary to maintain sodium balance, and that this is an 
important aspect of development and maintenance of spontaneous hypertension. 
 
 
 
 
 
 
114 
 
4.5 Acknowledgements 
 
The authors would like to acknowledge the assistance of the following student 
lab assistants that worked tirelessly in the development of the conplastic colony 
and phenotype screening of each colony generation: Aaron Fain, Erin Wyatt, 
Samuel Carmichael II, Timothy Bradshaw and Adesuwa Ighodaro.  The authors 
would also like to thank Kristen Blaker for her assistance in measuring urinary 
protein excretion.  
 
 
 
115 
 
 
Figure 4.1: Experimental schema of the acute salt study that allowed 
for rats to titrate their own salt and water. A: Illustrates the 
experimental design, with three experimental phases.  Rats were 
given 0.9% saline for the first 5 days, followed by hypertonic 2.0% for 
5 days, and then returned to 0.9% saline.  Blood pressures were 
taken after each of the three phases.  B: Illustrates BP differences 
throughout the entirely of the experiment.  BP was elevated in HT 
rats compared with NT rats, however, BP did not change with acute 
saline challenge (p>0.05). 
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Figure 4.2: Sodium intake throughout course of the experiment.  A: 
Illustrates the average daily sodium intake (µEq/day) for NT and HT 
rats.  B: Illustrates the average 5-day sodium intake for NT and HT 
rats.  HT rats ingested more sodium than NT rats when offered 2.0% 
saline (*p<0.05), however, HT rats ingested similar amounts of sodium 
in all three phases of the experiment.  NT rats ingested significantly 
less sodium (#p<0.05) when offered 2.0% saline, and continued to eat 
less when again offered 0.9% saline. 
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Figure 4.3: Average 5-day water intake (ml/day).  NT rats 
ingested significantly more water (#p<0.05) when offered 2.0% 
saline and again offered 0.9% saline.  NT rats also ingested 
significantly more water than HT rats (*p<0.05).  HT rats ingested 
significantly more water than when offered 2.0% saline (#p<0.05), 
but ingested similar amounts when again offered 0.9% saline. 
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Figure 4.4: Sodium excretion throughout the course of the 
experiment.  A: Illustrates the average daily sodium excretion 
(µEq/day) for NT and HT rats.  B: Illustrates the average 5-day 
sodium excretion for NT and HT rats.  HT rats excreted more 
sodium than NT rats when offered 2.0% saline (p>0.05), 
however, this amount did not reach statistical significance until 
rats were again offered 0.9% saline (*p<0.05). HT and NT rats 
maintained similar amounts of sodium in all three phases of the 
experiment.   
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Figure 4.5: Sodium balance throughout the course of the experiment.  A: 
Illustrates the cumulative daily sodium balance (µEq/day) for NT and HT 
rats.  B: Illustrates the average 5-day sodium balance for NT and HT 
rats.  Both NT and HT rats were in negative sodium balance throughout 
the course of the experiment, however HT rats exhibited greater 
variability while maintaining elevated  sodium natriuresis (*p<0.05).  This 
may be due to elevated arterial pressures.   
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Figure 4.6: Urinary protein excretion was maintained and normal 
in NT and HT BN/SHR-mtSHR for the entire experimental protocol.  
Therefore, renal function appeared to be normal and not different 
between NT and HT BN/SHR-mtSHR  (P>0.05). 
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Figure 4.7: Hypothetical pathway in which long term reduced NaCl 
sensitivity could activate the RAS, increasing sympathetic nerve activity 
and increases in arterial pressure.  Chronic pressure-natriuresis may be 
“essential” in the SHR, therefore underlie the development and 
maintenance of elevated arterial pressure. 
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5.1 Introduction 
 
Hypertension constitutes a primary and significant factor in the development of 
cardiovascular disease.  Despite major gains in the long-term treatment of 
hypertension, cardiovascular disease remains the number one cause of death 
and disability in developed countries.  Primary or essential hypertension is 
regarded as a multi-factorial disease, influenced by both genetic inheritance and 
environmental conditions that influence gene expression.  The genetic basis of 
hypertension has been focused primarily on inheritance and expression of 
nuclear genes (Tsuchida, Liu et al. 1994), despite the fact that mitochondria are 
present in multiple copies in each cell and have their own genome.  Additionally, 
and potentially of great importance, is the fact that OXPHOS depends on the 
coordinated expression of two separate but interactive genomes, nuclear and 
mitochondrial.  Numerous trans-factors involved with mtDNA replication, 
transcription and mRNA processing are nuclear encoded, including mtRNA 
polymerase, mtDNA polymerase, several regulatory transcription factors and 
mtRNA processing proteins (Hein and Kobilka 1995).   This nuclear-
mitochondrial interaction is essential to cellular health and function, and therefore 
may play a large role in the development of disease (Nowak 2002).   
 
Mitochondrial dysfunction has been implicated in a wide variety of genetic 
disorders (Wallace 1999; Taylor and Turnbull 2005) and alterations in 
mitochondrial function have been observed in conjunction with aging and 
development of hypertension in both rodents and humans (Schwartz, Duka et al. 
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2004; Wallace 2005; Chan, Wu et al. 2009; Kumarasamy, Gopalakrishnan et al. 
2010).  Recently, mitochondrial transfer RNA (tRNA) mutations were observed in 
a genetically focused population with a high incidence of essential hypertension 
(Osanai, Tanaka et al. 2001; Li, Liu et al. 2009).  Wilson et al. (2004) have 
described a correlation between a T4921C transition SNP, which lies in the 
mitochondrial tRNAlle gene (GenBank accession no. NC_001807) and 
hypertension.  The genetic association of mtDNA variants and tRNA mutations 
(Geraldes and King 2010) to type 2 diabetes and hypertension directly implicated 
mitochondrial dysfunction in development of cardiovascular disease and 
metabolic syndrome (Wallace 2005).  Taken together, there is significant 
evidence that altered mitochondrial genetic expression may have a significant 
role in the generation of cardiovascular disease phenotypes.  However, the 
regulatory mechanisms in which mitochondria and mitochondrial genes are 
expressed and regulated in disease is mostly unknown. 
 
In contrast, the role of the kidney in long-term blood pressure regulation and 
manifestation of hypertension is well known.  The importance of kidney function 
to modulate blood pressure has been shown by Lifton et al. (2001) demonstrating 
genetic variants in important renal pathways underlie all of the Mendelian 
disorders affecting blood pressure homeostasis (Inagaki, Churchill et al. 2006).  
Therefore, it is postulated that altered renal expression of genes may contribute 
significantly to the disease.  The goal of the present study was to determine the 
renal expression of mitochondrial protein-coding genes, the nuclear pathway that 
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regulates their expression and the relationship between heritable hypertension in 
a rat strain with localized mt-DNA from Okomoto-Aoki SHR.  The “conplastic” 
strain was developed by crossing a hypertensive female SHR with normotensive, 
male BN rats (BN/SHR-mtSHR) (Collett, Hart et al. 2013).  Hypertensive female 
offspring then were phenotypically selected and crossed with founder males for 
several generations.  All offspring had identical mitochondrial DNA of the 
progenitor SHR, barring any mutation.  The results of these studies document 
significant reduced expression of renal mtRNA and nuclear encoded regulatory 
elements in hypertensive male and female offspring.  The data suggest that 
reduced renal mtRNA expression may elicit hypertension by decreased 
OXPHOS.  
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5.2 Methods and Materials 
 
5.2.1 Animals 
 
All experiments were carried out in accordance with the AAALAC Guide to the 
Care and Use of Laboratory Animals and all protocols were previously approved 
by the University of Kentucky Institutional Animal Care and Use Committee.  A 
“conplastic” colony using phenotypic selection was employed.  The development 
and phenotypic characterization have been described in detail elsewhere (Collett, 
Hart et al. 2013).  The Aoki-Okamoto SHR/Brown Norway rat colony was 
developed by breeding a female SHR (Charles River Labs, Wilmington, MA) with 
2 different normotensive BN males (Charles River Labs, Wilmington, MA) 
(BN/SHR-mtSHR).  Beginning at 10 weeks of age, rats were phenotyped using tail 
cuff plethysmography (Kent Scientific, Torrington, CT).  Hypertensive female 
offspring were then back-crossed to the original progenitor BN males for 5 
subsequent generations.  
 
After repeated blood pressure recordings that assured consistent determination 
of arterial pressure, rats not scheduled for rebreeding were euthanized with an 
overdose of sodium pentobarbital (60 mg/kg i.p)., and organ tissues were rapidly 
frozen and stored for later analysis.   
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5.2.2 Measurement of arterial pressure. 
  
Systolic arterial pressure (SAP) was evaluated using in parents and offspring 
beginning at 10-12 weeks of age.  Phenotypes were assigned as either 
normotensive (NT: SAP ≤ 124mmHg), borderline hypertensive (BHT:  125 ≤ SAP 
< 150 mmHg) or hypertensive (HT: SAP ≥ 150mmHg).  Arterial pressure was 
derived from the average results of ≥5 measurements in each recording session.  
The average blood pressures of ≥5mmHg separate recording sessions with <5% 
variability were used to establish the phenotype of each animal.    Systolic 
pressures were used for the determination of the specific individual phenotype 
(Collett, Hart et al. 2013) . 
 
5.2.3 RNA Extraction and RT-PCR. 
   
Renal cortex and outer medulla homogenate, liver and left ventricular cardiac 
tissue were selected from HT and NT BN/SHR-mtSHR rats (n=20 NT; n=20 HT) as 
described above.  Total RNA was extracted with Trizol reagent (Invitrogen, 
Carlsbad, CA) and purified using RNeasy minicolumns (Qiagen Inc., Valencia, 
CA) according to the manufacturer’s protocol.  Possible genomic DNA was 
digested with DNase I (Qiagen Inc., Valencia, CA).  Concentration and purity of 
all RNA samples was determined by the Nanodrop ND-1000 spectrophotometer 
(Nanodrop Technologies, Wilmington, DE).  Extracted RNA was reverse-
transcribed into complementary DNA (cDNA) using qScript cDNA Supermix 
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(Quanta Biosciences, Gaithersburg, MD) in a total volume of 20µl using a 
MyCyler Thermal Cycler (Bio-Rad Laboratories, Hercules, CA).  
 
5.2.4 Quantitative Real-Time PCR. 
 
Quantitative Real-Time PCR was performed on a StepOnePlus Real-time PCR 
system (Applied Biosystems, Foster City, CA).  Real-time quantitative PCR 
amplifications were performed in triplicate on a 96-well plate.  Pre-designed 
TaqMan primers and hydrolysis probes for all genes of interest were purchased 
from Applied Biosystems (mt-ND1- Rn03296764_s1, mt-ND2- Rn03296765_s1, 
mt-ND3- Rn03296825_s1, mt-ND4- Rn03296781_s1, mt-ND4L- 
Rn03296792_s1, mt-ND5- Rn03296799_s1, mt-ND6- Rn03296815_s1, mt-CO1- 
Rn03296721_s1, mt-CO2- Rn03296737_s1, mt-CO3- Rn03296820_s1, mt-CYB- 
Rn03296746_s1, mt-ATP6- Rn03296710_s1, mt-ATP8- Rn03296716_s1, NRF1- 
Rn01455958_m1, NRF2a- Rn01767215_m1, NRF2b-Rn01514289_g1, Pgc1α-
Rn00598552_m1,  Tfam-Rn00580051_m1, Cyc1-Rn01504159_g1, Cox6c-
Rn00820983_gH, GAPDH- Rn01775763_g1).  Primers and probes were verified 
and operating at similar efficiencies.  Target gene and endogenous control 
amplicons were labeled with either FAM or VIC.  The levels of glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) RNA expression were measured in all 
samples to normalize gene expression for sample-to-sample differences in RNA 
input, RNA quality and reverse transcription efficiency.  Each sample was 
analyzed in triplicate, and the expression was calculated according to the 
2−ΔΔCt method (Bright and Mochly-Rosen 2005; Coble, Johnson et al. 2014). 
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5.2.5 Citrate Synthase Assay.  
 
Citrate synthase activity was determined in homogenates prepared from kidney 
tissue using a citrate synthase assay kit (CS0720; Sigma-Aldrich, St. Louis, 
MO). Total muscle protein was determined in triplicate by the method of Bradford 
(Buchholz, Dundore et al. 1991) and the protein concentration of all samples was 
equalized. Citrate synthase activity was determined based on the formation of 2-
nitro-5-thiobenzoic acid at a wavelength of 412 nm at 25°C on a microplate 
absorbance reader (iMark; BIO RAD, Hercules, CA). In each well, 8 μl of sample 
was added to a reaction medium containing 178 μl of assay buffer, 2 μl of 30 
mmol/L acetyl coenzyme A, and 10 mmol/L 2-nitro-5-thiobenzoic acid. The 
baseline solution absorbance was recorded, reactions were initiated by the 
addition of 10 μl of oxaloacetic acid, and the change in absorbance measured 
every 15 seconds for 2 minutes. 
 
5.2.6 Cytochrome Oxidase Histochemistry.  
  
Cytochrome oxidase (CO) activity was determined in fresh frozen sections 
(20µm) in kidney, liver and heart tissue, as described previously (Whitfield-
Rucker and Cassone 2000).  Briefly, fresh frozen tissue was sectioned on a 
cryostat at 20 µm.  Slides were immersed in 0.5% glutaraldehyde in 0.1% 
phosphate buffer for 5 minutes.  Slides were then incubated for 2 hours in a 
diaminobenzidene (DAB)/cytochrome c solution (preceded by 5 minutes of 
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sparged oxygen) at 37ºC.  Slides were then postfixed in 10% formalin for 15 
minutes.  Finally, slides were immersed in a serious of ethanol dehydration steps: 
50, 70, 90, 95, 100% ethanol (30 seconds each) and xylene (2 changes, 5 
minutes each).  Slides were then coverslipped using Histomount (Life 
Technologies) and dried overnight.  Colorometric change was used as a direct 
measurement of OXPHOS, in which darker color indicated higher metabolically 
active tissue.  Relative density per area was calculated using ImageJ (NIH). 
 
5.2.7 Statistical Analysis.  
 
Blood pressures and citrate synthase activity among animals were initially 
analyzed by 1-way analysis of variance (ANOVA) followed by post-hoc 
comparisons using the Bonferroni t-test.  Tissue mRNA expression levels were 
analyzed using Mann-Whitney U Test comparisons.  The 0.05 level of probability 
was utilized as the criterion of significance.  All statistical analyses were 
performed using GraphPad Prism 4.0 (GraphPad Software, Inc., La Jolla, CA).  
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5.3 Results 
 
5.3.1 Evaluation of mt-gene expression 
 
Quantitative real-time PCR was used to identify genes differentially expressed in 
renal tissue from hypertensive and normotensive BN/SHR-mtSHR rats.  Multiple 
mtDNA encoded genes of the mitochondrial respiratory chain were significantly 
reduced in renal, but not liver or cardiac tissue of HT BN/SHR-mtSHR, including 
five complex I, one complex III, three complex IV and both subunits of ATP 
synthase.  The well-established pathway in mammalian cells for mt-transcription 
initiation was evaluated using qPCR.  Tfam, NRF1, NRF2a, NRF2b and Pgc-1α 
were all downregulated in the kidney, but not elsewhere, of HT BN/SHR-mtSHR .  
 
5.3.1.1 Complex I: NADH Dehydrogenase 
 
Seven of the forty six genes that encode vital proteins for complex I of the 
electron transport chain are mt-encoded.  The renal mtRNA expression of five of 
the seven were significantly reduced in hypertensive versus normotensive 
BN/SHR-mtSHR.  mt-ND1 was reduced ~3.7 fold in HT BN/SHR-mtSHR (P<0.05).  
mt-ND3 was reduced ~2.6 fold in HT SHR/BN-mtSHR (P<0.01).  mt-ND4 was 
reduced ~10.8 fold in HT SHR/BN-mtSHR (P<0.05).  mt-ND4L was reduced ~7.7 
fold in HT SHR/BN-mtSHR (P<0.05).  mt-ND5 was reduced ~2.7 fold in HT 
SHR/BN-mtSHR (P<0.05).  mt-ND6 was reduced ~1.7 fold in HT SHR/BN-mtSHR 
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(P>0.05) (Figure 5.1A).  mt-ND2 was not different between the two phenotypes 
(P>0.05).  
 
5.3.1.2 Complex 3: Cytochrome bc1 Complex 
 
One of the eleven genes that encode vital proteins for complex three of the 
electron transport chain is mt-encoded. The renal mtRNA expression of mt-
encoded cytochrome b (mt-CYB) was significantly reduced in hypertensive 
versus NT BN/SHR-mtSHR.  mt-CYB was reduced ~5 fold in HT BN/SHR-mtSHR 
(P<0.05) (Figure 5.1B).  
 
5.3.1.3 Complex 4: Cytochrome C oxidase 
 
Three of the thirteen genes that encode vital proteins for complex IV of the 
electron transport chain are mt-encoded.  All three genes were significantly 
reduced in hypertensive versus normotensive BN/SHR-mtSHR.  mt-CO1 was 
reduced ~3.2 fold in HT BN/SHR-mtSHR (P<0.05), mt-CO2 was reduced ~3.6 fold 
in HT BN/SHR-mtSHR (P<0.01), and mt-CO3 was reduced 4.1 fold in HT 
BN/SHR-mtSHR (P<0.01) (Figure 5.1C).  
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5.3.1.4 Complex V: ATP synthase 
 
Two of the sixteen genes that encode vital proteins for ATP synthase of the 
electron transport chain are mt-encoded.  mt-ATP6 was reduced ~2.3 fold in HT 
BN/SHR--mtSHR (P<0.05), while mt-ATP8 was reduced ~3.1 fold in HT BN/SHR-
mtSHR (P<0.05) (Figure 5.1D).  
 
5.3.1.5 Tissue expression in Liver and Heart 
 
Expression levels of several mt-genes were evaluated in both the liver and heart 
of HT and NT BN/SHR-mtSHR as described above.  mt-CYB, mt-CO2 and mt-
ND1, mt-ATP6 were shown to be not different (P>0.05) between the HT and NT 
BN/SHR-mtSHR liver or heart tissues.  This is in contrast to renal tissue wherein 
each of these genes exhibited reduced expression in HT vs. NT animals (Figure 
5.2).    
 
5.3.2 Evaluation of Oxidative Phosphorylation: Cytochrome Oxidase 
Histochemistry 
 
CO activity was measured densitometrically in kidney, liver and heart sections 
(20µm) in NT (n=6) and HT (n=6) BN/SHR-mtSHR.  CO activity was significantly 
lower (p<0.05) in the kidney, but not the liver or heart in HT BN/SHR-mtSHR 
(Figure 5.3). 
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5.3.3 Evaluation of Trans-Regulatory Factors 
 
The well-established pathway in mammalian cells for mt-transcription initiation 
was evaluated using qPCR.  Pgc1a, NRF1, NRF2a, NRF2b and Tfam were all 
downregulated in the kidney, but not liver tissue, of HT compared to NT BN/SHR-
mtSHR (n=20).  The pathway leading to reduced mitochondrial gene expression is 
summarized in (Figure 5.7). 
 
5.3.3.1 Peroxisome Proliferator-Activated Receptor Gamma Co-Activator 1-alpha 
(PGC-1α) 
 
PGC-1α regulates NRF-dependent transcription, increases expression of both 
mitochondrial and nuclear encoded genes of oxidative phosphorylation and 
induces mitochondrial biogenesis.  HT BN/SHR-mtSHR exhibited ~2.5 fold 
reduction in PGC-1α mRNA in kidney tissue compared with NT BN/SHR-mtSHR 
(P<0.05) (Figure 5.4A).   
 
5.3.3.2 Nuclear Respiratory Factors 
 
Nuclear respiratory factors 1 and 2 are well characterized transcriptional 
activators of genes involved in assembly of the respiratory apparatus, as well as 
constituents of the mtDNA transcription and replication machinery (Kelly and 
Scarpulla 2004).  A main factor involved in mtDNA transcription is Tfam, whose 
expression is regulated by NRF1.  All three NRFs were reduced in the kidney, 
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but not liver of HT compared to NT BN/SHR-mtSHR.  Renal NRF1 mRNA 
expression was reduced ~1.8 fold in HT BN/SHR-mtSHR compared with NT 
BN/SHR-mtSHR (P<0.05) (Figure 4B). Renal NRF2a mRNA expression was 
reduced ~2.3 fold in HT BN/SHR-mtSHR compared with NT BN/SHR-mtSHR 
(P<0.05) (Figure 4C). Renal NRF2b mRNA expression was reduced ~1.9 fold in 
HT BN/SHR-mtSHR compared with NT BN/SHR-mtSHR (P<0.05) (Figure 5.4D).  
 
5.3.3.3 Mitochondrial Transcription Factor A (Tfam) 
 
Tfam is a key activator of mammalian mitochondrial transcription.  Kidney, but 
not liver tissue exhibited reduced Tfam mRNA expression ~2.5 fold in HT 
BN/SHR-mtSHR compared with NT BN/SHR-mtSHR (P<0.05) (Figure 5.4E).  
 
5.3.4 Nuclear-Encoded Mitochondrial Genes: Cytochrome C-1 (Cyc1), 
Cytochrome C Oxidase, Subunit Vic (Cox6c) 
 
In order to assess the downstream pathways of the nuclear encoded regulatory 
elements, nuclear-encoded mitochondrial gene expression were assessed.  
There was no difference in the renal mRNA expression of CYC or Cox6c 
between NT (n=10) and HT (n=10) BN/SHR-mtSHR (P>0.05) (Figure 5.5). 
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5.3.5 Evaluating Mitochondrial Number: Citrate Synthase Assay 
 
To quantify mitochondrial number, citrate synthase activity was measured in 
kidney homogenates of NT (n=10) and HT (n=10) BN/SHR-mtSHR (Figure 5.6).  
There was no difference between the two phenotypes (P=0.9676), indicating that 
mitochondrial number was not driving the reduced transcript expression in HT 
BN/SHR-mtSHR kidneys. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
137 
 
5.4 Discussion 
 
There is significant evidence that mitochondria and the mitochondrial genome 
may be important in the development of hypertension (Wallace 1999; Osanai, 
Tanaka et al. 2001; Schwartz, Duka et al. 2004; Taylor and Turnbull 2005; de 
Cavanagh, Toblli et al. 2006; Lopez-Campistrous, Hao et al. 2008; Kumarasamy, 
Gopalakrishnan et al. 2010).  Of particular interest may be the nature of 
mitochondrial inheritance, being strictly maternal, and of female SHR origin.  The 
results of the current study provide evidence that gene expression variation in 
renal mitochondrial genes encoding respiratory chain complexes is related to 
hypertension in rats stemming from a SHR/BN conplastic breeding paradigm.  
This breeding method provided a continuous passing of the maternal 
mitochondrial genome, while mixing the inherited nuclear genome between the 
maternal SHR and paternal BN with each succeeding generation. We have 
reported the maintenance of arterial systolic hypertension for 6 consecutive 
generations in this conplastic strain despite the reduction in maternally derived 
nuclear genome (Collett, Hart et al. 2013).  Results from the current study show 
mitochondrial protein-coding genes critical for OXPHOS exhibited significantly 
reduced expression in the kidney, but not the in the liver or heart, in HT BN/SHR-
mtSHR compared with NT BN/SHR-mtSHR.  Additionally, in HT BN/SHR-mtSHR, 
nuclear genes involved in mitochondrial biogenesis and transcription (PGC-1α, 
NRF1, NRF2a/b, Tfam), exhibited reduced expression in the kidney, but not liver, 
compared with NT BN/SHR-mtSHR (Figure 5.3).  Thus, kidney-specific reduction 
in expression of both mitochondrial and nuclear genes critical to OXPHOS is 
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associated with the manifestation of hypertension in rats with intact SHR 
mitochondrial genome but minimal SHR nuclear genome. 
 
Recently, Lee et al. (2014) postulated that increased mitochondrial activity in 
proximal convoluted tubule cells of young, normotensive SHR may contribute to 
the development of hypertension at adulthood.  These studies show that various 
parameters of mitochondrial activity were elevated in very young SHR prior to the 
onset of hypertension, while mt-gene expression remained unchanged.   Our 
study documents mitochondrial genes encoding proteins of each mitochondrial 
subunit of mRNA were reduced in renal tissue of HT BN/SHR-mtSHR compared 
with NT BN/SHR-mtSHR. It is possible that mitochondrial activity is elevated in 
renal proximal tubules of very young SHR prior to the onset of hypertension.  As 
the development of hypertension progresses in the maturing SHR, renal 
mitochondrial gene expression may then decline which in turn significantly 
contributes to the further elevation of blood pressure.  Ongoing and future studies 
are being conducted to address this possible relationship and mechanism 
specific to the SHR.  
 
The viability of individual electron transport chain subunits and the potential for 
disease has been evaluated.  Altered function of complex I has been linked to 
cardiovascular disease (Antonicka, Ogilvie et al. 2003; Lopez-Campistrous, Hao 
et al. 2008).  Lopez-Campistrous et al. (2008) revealed defects in complex I in 
the brainstem of SHR, resulting in increased reactive oxygen species production, 
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decreased ATP synthesis and impaired respiration in hypertension .  Results 
from our current study indicate reduced genetic expression of most the mt-genes 
coding for Complex I, suggesting that defects in complex I function may be due 
to reduced mitochondrial gene expression.  Altered function of complex III, a 
major site of superoxide formation and ROS production, may play an important 
role in renal mitochondrial ETC dysfunction and cardiovascular disease.  Similar 
to these findings, Das et al. (1990) reported that the regulation of ATP synthase 
is abnormal in SHR cardiac cells, as demonstrated by the inability to respond to 
acute increases in energy demand compared to cells from normotensive rats .  
Data from our study indicate that mt-gene expression is reduced in kidneys, a 
key organ in blood pressure control.  Furthermore, kidneys of hypertensive rats 
had reduced CO staining, indicating reduced oxidative phosphorylation 
compared with NT rats (Figure 5.3).  This could have profound effects, as the 
kidney has high metabolic demand, particularly in regulating salt and water 
balance, and hence, arterial pressure.  Taken together, the altered function of 
ETC subunits derived from decreased kidney-specific mt-gene expression may 
have several implications to the development of hypertension. 
 
PGC-1α plays a central role in regulating mitochondrial content and function 
within cells, because of its ability to co-activate and augment several promoters 
of nuclear-encoded mitochondrial genes, as well as regulating mitochondrial 
transcription via the NRF-Tfam pathway (Wu, Puigserver et al. 1999).  PGC-1α 
regulates NRF-dependent transcription, increases expression of both 
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mitochondrial and nuclear encoded genes of oxidative phosphorylation and 
induces mitochondrial biogenesis (Scarpulla 2002).  It has been shown that 
metabolic functions are controlled by PGC-1α  in a tissue specific manner in 
brown fat, muscle and liver (Puigserver 2005), however kidney regulation of  
PGC-1α  and its effectors is unknown.  Results from this study show a clearly 
coordinated reduction of the kidney-specific expression of nuclear and 
mitochondrial genes vital to OXPHOS coinciding with the manifestation of 
hypertension (Figure 5.7).  It is likely that this nuclear-mitochondrial gene down 
regulation is being driven by upstream events.  Although the upstream signaling 
involved in the activation/reduction of PGC-1α is yet to be fully elucidated, 
several pathways have been described.  Briefly, the activity of PGC-1α can be 
modulated by numerous post-translational events, including phosphorylation by 
AMP kinase (AMPK)(Fan, Rhee et al. 2004)  and cAMP response element-
binding protein (CREB) (Fernandez-Marcos and Auwerx 2011), among others 
(García-Giménez, Gimeno et al. 2011).   
 
Mitochondrial biogenesis and transcription have been thought to be regulated by 
the same nuclear-mitochondrial pathway described above (Scarpulla, Vega et al. 
2012).  However, mitochondrial number between NT and HT rats were not 
different as measured by citrate synthase activity (Figure 5.6).  Mitochondrial 
encoded gene ND2 of complex 1 was also not different between the NT and HT 
phenotypes (Figure 5.1A).   Subunit ND2 has been shown to play a significant 
role in the assembly and/or stability of Complex I (Antonicka, Ogilvie et al. 2003).  
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Results from our current study reinforce the importance of ND2 in electron 
transport chain integrity, as it was the only subunit of complex I that showed no 
expression difference in kidneys between the two phenotypes.  In order to further 
assess the downstream pathways of the nuclear-encoded regulatory elements, 
the expression of two separate nuclear-encoded mitochondrial genes were 
assessed.  Interestingly, other nuclear-encoded mitochondrial genes known to be 
regulated by the PGC-1α-NRF-Tfam pathway were not different.  Neither renal 
Cytochrome C-1 (Cyc1) nor cytochrome c oxidase subunit Vic (Cox6c) were not 
different between HT and NT BN/SHR-mtSHR (Figure 5.5).  This phenomenon 
has several implications.  First, biogenesis and transcription of mitochondrial 
genes, though known to be regulated by the PGC-1α pathway, may in fact be 
regulated in a more complex manner than previously thought.  Furthermore, 
mitochondrial gene expression appears to be regulated in a tissue-specific 
manner.  If this is the case, our data indicate that tissues of high metabolic 
activity may have a critical role in the development of disease.  Therefore, it is 
plausible that altered OXPHOS could impact renal function, which is the 
cornerstone of blood pressure regulation and development of hypertension. 
 
One of the more interesting aspects of this study is a potential ETC dysfunction 
driven by transcript differences in the kidneys, but not in other tissues, of mt-
genes and the nuclear trans-factors that regulate them.  Cytochrome oxidase 
serves as an endogenous metabolic marker.  As shown in Figure 5.3, CO 
staining was significantly reduced in the kidneys, but not liver or heart of HT 
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BN/SHR-mtSHR, indicating that the kidneys of hypertensive rats had reduced 
OXPHOS.  Altered renal function has been well recognized as a key factor in the 
development and maintenance of hypertension (Bianchi, Fox et al. 1974; Curtis, 
Luke et al. 1983; Dilley, Stier et al. 1984; Guyton 1990; Cowley and Roman 
1996; Ichihara, Inscho et al. 1997).  One such mechanism that may be 
responsible is altered regulation of the renin-angiotensin system.  The RAS 
serves as one of the most powerful regulators of blood pressure.    The 
interactions among RAS and altered mitochondrial function has been advanced 
recently by Benigni et al. (2009).  Deletion of the Agtr1a gene resulted in the 
reduced age-related cardio-renal complications, improved mitochondrial 
biogenesis, and increased longevity in mice.  Treatment with antioxidants, 
mitochondrial superoxide dismutase mimetics, and AT1r blockers decreased 
vascular O2- production and attenuated development of hypertension in SHR 
(Park, Touyz et al. 2002),(Rodriguez-Iturbe, Zhan et al. 2003),(Shokoji, 
Nishiyama et al. 2003).  De Cavanagh et al. (2006) demonstrated that oxidative 
stress is associated with mitochondrial dysfunction in SHR, and that this 
dysfunction is attenuated with AT1r blockade with losartan .   The presence and 
abundance of renal AT1r is related to the propagation of the HT phenotype in 
BN/SHR-mtSHR.  We have previously shown that HT BN/SHR-mtSHR exhibit 
elevated AT1r mRNA (Agtr1a) expression compared to NT BN/SHR-mtSHR, while 
the renal and systemic expression of renin, angiotensinogen, and angiotensin-
converting enzymes were not different (Collett, Hart et al. 2013).  HT BN/SHR-
mtSHR exhibited elevated AT1r protein compared with NT BN/SHR-mtSHR, and this 
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increase was positively correlated with elevated systolic BP (Collett, Hart et al. 
2013).  These data highlight a renal-specific phenomenon that appears to play a 
role in the pathology of hypertension in these animals. 
 
Another mechanism that may underlie reduced mt-gene expression is altered 
activity of the sympathetic nervous system.  Elevated RSNA plays an important 
role in the development and maintenance of hypertension in the SHR (Judy, 
Watanabe et al. 1976; 1995; Karim, Defontaine et al. 1995).   Increases in RSNA 
decrease urinary sodium and water excretion by increasing renal tubular water 
and sodium reabsorption throughout the nephron, decrease renal blood flow and 
glomerular filtration rate by constricting the renal vasculature, and increase 
activity of the renin-angiotensin system by stimulating renin release from 
juxtaglomerular granular cells (DiBona and Kopp 1997; Osborn, Plato et al. 1997; 
DiBona 2000).  Activation, or overactivation of adrenergic receptors may trigger 
downstream effects, altering expression of PGC-1α through phosphorylation of 
AMP kinase (AMPK)(Fan, Rhee et al. 2004), cAMP response element-binding 
protein (CREB) (Fernandez-Marcos and Auwerx 2011) or others (García-
Giménez, Gimeno et al. 2011) to ultimately decrease mt-gene expression. 
 
Whenever mitochondrial disturbances inhibit electron transport, electrons are 
forwarded into an increased generation of ROS (Wallace 2005).  Increased 
mitochondrial ROS is linked to metabolic diseases such as aging, diabetes and 
hypertension (Hagen, Yowe et al. 1997; Kristal, Jackson et al. 1997; Addabbo, 
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Montagnani et al. 2009).  Mitochondria are a major site of oxygen consumption 
and oxidative stress due to generation of ROS, where complexes I and III are the 
main sites of mitochondrial superoxide formation (Votyakova and Reynolds 
2001).  Recently, mitochondrial ETC dysfunction has been shown to directly 
cause oxidative stress during hypertension.  Chan et al. (2009) reported that 
mitochondrial ROS production in the rostral ventrolateral medulla is elevated in 
SHRs, and that ROS dependent inhibition of mitochondrial ETC complexes I, II 
and III resulted in a feed-forward production of ROS, as well as defects in anti-
oxidant production.  Ballinger et al. (2000) have demonstrated that  reactive 
oxygen species decreased mtRNA transcripts, mitochondrial protein synthesis 
and decreased cellular ATP levels.  Taken together, ROS decreases OXPHOS, 
and decreased OXPHOS increases ROS, both of which contribute to 
hypertension (Figure 5.7).   Therefore, in our studies, the reduction of renal gene 
expression may lead to the development and maintenance of hypertension.  
 
In summary, we present novel data documenting a decrease in a well-defined 
nDNA-mtDNA interactive pathway resulting in decreased mtDNA transcripts of 
proteins vital to OXPHOS.  This coordinated reduction of nuclear-mitochondrial 
OXPHOS genes and its potential role in the development of hypertension until 
now was largely unknown (Figure 5.7).  Though the exact mechanisms driving 
this reduction in gene expression is currently not known, it is clear that reduced 
mt-gene expression in the kidney coincides with the development of hypertension 
in BN/SHR-mtSHR.  Using our current model, where the nuclear genome is 
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increasingly BN while maintaining the SHR mitochondrial genome, in 
combination with other similar models, the relevance of the specific control of 
each of these genomes and how they may contribute to disease may be 
revealed.  Furthermore, the nuclear-mitochondrial gene expression interactions 
may also be critically important in the manifestation of the progression of the 
renal disease process and ultimate development of hypertension.  Future studies 
focused on elucidating the upstream mechanisms driving the reduced expression 
and subsequent potential mitochondrial dysfunction will determine if this 
phenomenon may directly lead to the development of heritable hypertension. 
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Figure 5.1: Quantitative Real-Time PCR mt-genes across 4 complexes of 
ETC. NT animals are in white, HT animals are in black.  A: mt-ND1 was 
reduced ~3.7 fold in HT BN/SHR-mtSHR (*P<0.05).  mt-ND3 was reduced 
~2.6 fold in HT SHR/BN-mtSHR (**P<0.01).  mt-ND4 was reduced ~10.8 fold 
in HT SHR/BN-mtSHR (*P<0.05).  mt-ND4L was reduced ~7.7 fold in HT 
SHR/BN-mtSHR (P<0.05).  mt-ND5 was reduced ~2.7 fold in HT SHR/BN-
mtSHR (P<0.05).  mt-ND6 was reduced ~1.7 fold in HT SHR/BN-mtSHR 
(P>0.05). mt-ND2 was not different between the two phenotypes (P>0.05). 
B:  mt-CYB was reduced ~5 fold in HT BN/SHR-mtSHR (*P<0.05).  C:  mt-
CO1 was reduced ~3.2 fold in HT BN/SHR-mtSHR (*P<0.05), mt-CO2 was 
reduced ~3.6 fold in HT BN/SHR-mtSHR (P<0.05), and mt-CO3 was reduced 
4.1 fold in HT BN/SHR-mtSHR (P<0.05).  D: mt-ATP6 was reduced ~2.3 fold 
in HT BN/SHR--mtSHR (*P<0.05), while mt-ATP8 was reduced ~3.1 fold in 
HT BN/SHR-mtSHR (*P<0.05). 
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Figure 5.2: Quantitative Real-Time PCR of representative mt-genes of 
complex I-V were evaluated in liver and heart tissue of HT and NT 
BN/SHR-mtSHR. NT animals are in white, HT animals are in black.  A: 
mt-CYB, B: mt-CO2, C: mt-ND1, and D: ATP6 were shown to be not 
different (P>0.05) between the HT and NT BN/SHR-mtSHR liver and 
heart compared with kidney tissue. 
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Figure 5.3: Cytochrome oxidase staining was significantly 
lower in the kidney of HT vs. NT BN/SHR-mtSHR (P<0.05). 
However, CO staining was not different in liver (p=0.3828) or 
heart (p=0.6664) of HT vs.  NT BN/SHR-mtSHR.  NT are in 
white, HT in black.   
 
 
 
150 
 
 
Figure 5.4: Quantitative Real-Time PCR graphs of the well-established nuclear-
mitochondrial induction of mitochondrial gene transcription.    NT animals are in 
white, HT animals are in black.  A. Peroxisome proliferator-activated receptor 
gamma coactivator 1-alpha (PGC-1α).  Renal  PGC-1α mRNA expression was 
reduced ~2.5 fold in HT BN/SHR-mtSHR compared with NT BN/SHR-mtSHR 
(P<0.05).  B. Nuclear Respiration Factor (NRF) 1.  Renal NRF1 mRNA expression 
was reduced ~1.8 fold in HT BN/SHR-mtSHR compared with NT BN/SHR-mtSHR 
(P<0.05). C. Nuclear Respiration Factor 2A.  Renal NRF2A mRNA expression was 
reduced ~2.3 fold in HT BN/SHR-mtSHR compared with NT BN/SHR-mtSHR 
(P<0.05).  D. Nuclear Respiration Factor 2B.  Renal NR2B mRNA expression was 
reduced ~1.9 fold in HT BN/SHR-mtSHR compared with NT BN/SHR-mtSHR 
(P<0.05). E. Mitochondrial Transcription Factor A (Tfam).  Renal Tfam mRNA 
expression was reduced ~2.5 fold in HT BN/SHR-mtSHR compared with NT 
BN/SHR-mtSHR (P<0.05)   Expression levels were not different in the liver 
(P>0.05) in HT BN/SHR-mtSHR compared with NT BN/SHR-mtSHR for any of the 
transcription factors.   
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Figure 5.5: Quantitative Real-Time PCR of nuclear-encoded 
mitochondrial genes.  NT animals are in white, HT animals are in black.    
Neither renal   A: Cytochrome C-1 (Cyc1) (P=0.3928) nor B: cytochrome 
c oxidase, subunit Vic (Cox6c)(P=0.7618) were different between NT and 
HT BN/SHR-mtSHR. 
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Figure 5.6: Citrate synthase activity was not different in renal 
tissue of NT versus HT BN/SHR-mtSHR.  Mitochondrial number 
was not different between the two phenotypes (P=0.9676).   
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Figure 5.7: Hypothetical nuclear-mitochondrial pathway driving reduced mtDNA 
transcription, ultimately leading to elevated arterial pressure and hypertension.  
The pathway is clearly reduced in the kidney, but not liver of HT BN/SHR-mtSHR 
compared with NT BN/SHR-mtSHR.   
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CHAPTER 6 
GENERAL CONCLUSIONS AND DISCUSSION 
 
The goal of this dissertation was to determine the roles that specific humoral, 
genetic and genomic mechanisms play in the manifestation and maintenance of 
spontaneous hypertension. This was accomplished with two major hypotheses.  
One underlying hypothesis tested was that specific aspects of the renin-
angiotensin system, in particular, the location and abundance of AT1 receptors 
was associated with hypertension, which is supported by data presented in 
Chapters 3 and 4.  Renal- and hypothalamic-specific expression of AT1 receptors 
was associated with hypertension in rats with decreasing SHR nuclear genome.  
Chapter 4 data further support tissue-specific expression, suggesting that 
elevated hypothalamic AT1r protein may be associated with an impaired ability to 
sense orally ingested sodium.   The second major hypothesis tested was that the 
maternal inheritance of the mitochondrial genome might play a specific role in the 
development of hypertension.  Data presented in Chapter 2 supports a dominant 
expression of the hypertensive phenotype stemming from a single SHR female 
rat, despite the continual reduction of the SHR nuclear genome.  With the 
dominance of the hypertensive phenotype, the role of the mitochondria, 
mitochondrial gene expression and mitochondrial function were investigated.  
Data presented in Chapter 5 supports an important role that the mitochondria 
and the regulation of the mitochondrial genome play in the development of 
hypertension.  Hypertensive BN/SHR-mtSHR exhibited significant reductions of 
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mtRNA compared to NT rats of the same strain, in nearly all of the 
mitochondrially protein encoded genes, and this reduction coincided with a 
reduction of OXPHOS.  Furthermore, data presented in Chapter 5 indicates an 
important role for tissue-specific expression and function of the mitochondria, 
with the reduced expression of genes critical to OXPHOS, as well as reduced 
OXPHOS itself, occurring in the kidney but not liver or heart in HT BN/SHR-
mtSHR.  However, this data also implicates an important role of the nuclear factors 
that regulate mitochondrial gene expression and biogenesis, leading to a future 
hypothesis that it is not mitochondrial inheritance, but something upstream of the 
mitochondrion, for instance the RAS that is driving mitochondrial dysfunction, 
ultimately contributing to hypertension.  Presented in this final chapter is a 
discussion of how these findings relate to each other and possible future 
directions to take.  I postulate that Ang II binding to its type 1 receptor plays a 
significant role in the renal downregulation of mitochondrial gene expression and 
OXPHOS, thus contributing significantly to the development and maintenance of 
hypertension in BN/SHR-mtSHR (Figure 6.1). 
 
Data presented in this dissertation supports the important role of the kidney in the 
development and maintenance of hypertension.  HT BN/SHR-mtSHR exhibited 
elevated AT1 gene and protein expression in the kidneys, but not the liver or 
heart compared with NT BN/SHR-mtSHR.  Transcript analyses of systemic 
aspects of RAS were not different between the two phenotypes in the BN/SHR-
mtSHR colony.  This increase in kidney AT1r expression coincided with a decrease 
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in mitochondrial gene expression in HT BN/SHR-mtSHR.  HT rats exhibited a 
decrease in the well-defined nDNA-mtDNA interactive pathway resulting in 
decreased mtDNA transcript expression of proteins vital to OXPHOS (Figure 
6.1).  This coordinated reduction of nuclear-mitochondrial OXPHOS genes and 
its potential relationship to the development of hypertension until now was largely 
unexplored.  Though the exact mechanisms driving this reduction in gene 
expression is not known, it is clear that reduced mt-gene expression in the kidney 
coincides with the development of hypertension in BN/SHR-mtSHR.  Furthermore, 
data presented in Chapter 5 indicates that HT rats exhibited reduced OXPHOS, 
as HT rats exhibited decreased cytochrome oxidase staining compared with NT 
BN/SHR-mtSHR, and this decrease was observed only in the kidney.  What then 
does this mean in terms of the development of spontaneous hypertension?  Does 
reduced mitochondrial gene transcription, and ultimately reduced OXPHOS lead 
to reduced renal function, which then initiates chronic elevated arterial pressure?  
Data presented in Chapter 4 indicates that renal function was normal between 
NT and HT BN/SHR-mtSHR.  Both NT and HT rats were in negative sodium 
balance, while exhibiting similar proteinuria.  Since that is the case, it may be 
possible that reduced renal tubular mitochondrial function makes sodium 
handling in the kidney less efficient, therefore requiring chronic pressure-
natriuresis and a resetting of the renal function curve.  This hypothesis seems 
plausible, with a reduced ability to “sense” orally ingested NaCl, HT rats require 
elevated arterial pressure to maintain sodium balance, shifting the renal-function 
 
 
157 
 
curve to the right.  Hence, the HT BN/SHR-mtSHR maintain sodium balance, but 
at the expense of the morbidity of hypertension.   
 
As discussed in Chapters 1, 3 and 4, Ang II plays a pivotal role in the regulation 
of blood pressure, volume, and electrolyte balance.  The angiotensin II, type 1 
receptor has been extensively evaluated in rodents and has subsequently 
become a target as a causal factor in the development of spontaneous 
hypertension.  Reja et al. (2006) showed that gene expression levels of AT1r, 
extracellular signal-regulated kinase 2 and phosphatidylinositol 3-kinase were 
significantly higher in the PVN, RVLM and adrenal medulla in SHR compared to 
normotensive WKY rats.  Raizada et al. (1993) showed that AT1r mRNA was 
higher in the hypothalamus and brainstem of hypertensive SHR compared to 
normotensive WKY rats.  Furthermore, Gyurko et al. (1993) showed that 
antisense inhibition of AT1 receptor mRNA in the brain reduces the magnitude of 
hypertension in adult SHR.  Data from our studies strongly supports the notion 
that tissue-specific elevation of AT1 receptors may play a role in SHR-derived 
hypertension.  In fourth generation BN/SHR-mtSHR , where the nuclear genome of 
the original SHR accounts for only ~6.2%, HT rats had significantly higher AT1r 
protein expression than normotensive rats in both kidney and hypothalamic 
tissue.  Average SAP and tissue expression of AT1r were positively correlated, 
indicating that tissue-specific expression of AT1r expression may critically impact 
the development and maintenance of spontaneous hypertension.  In HT and NT 
BN/SHR-mtSHR rats across all generations, we saw in increase in the kidney 
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expression of AT1r mRNA associated with hypertension. Increased AT1r could 
potentially have drastic effects on the cardiovascular system, and subsequently, 
the pathogenesis of hypertension.  Ang II’s effect in the kidney would be 
exacerbated, increasing proximal tubular sodium reabsorption and decreasing 
renal blood flow.  In the hypothalamus, elevated AT1r expression could increase 
sympathetic nervous activity and/or vasopressin secretion, subsequently 
increasing vascular resistance and sodium and water retention (Scherrer 1959; 
Osborn and Camara 1997; Chen and Toney 2001).   
 
Significant evidence suggests that the RAS plays a role in altering mitochondrial 
function.  ACE inhibitors and ARBs reduce age-related mitochondrial dysfunction 
and protect against cardiac mitochondrial dysfunction following acute ischemic 
attack (DE CAVANAGH, PIOTRKOWSKI et al. 2003; Monteiro, Duarte et al. 
2005; de Cavanagh, Toblli et al. 2006).  Ang II can induce oxidant stress by 
enhancing the generation of both NO (Pueyo, Arnal et al. 1998) and NAD(P)H 
oxidase-derived superoxide (Rueckschloss, Quinn et al. 2002). Ang II can also 
induce endothelial NO synthase uncoupling, i.e., switching from NO to 
superoxide production (Mollnau, Wendt et al. 2002). Furthermore, Ang II has 
been shown to stimulate mitochondrial reactive oxygen species (mtROS) 
production.  Increased mtROS has been linked to metabolic diseases such as 
aging, diabetes and hypertension (Hagen, Yowe et al. 1997; Kristal, Jackson et 
al. 1997; Addabbo, Montagnani et al. 2009).  Mitochondria are a major site of 
oxygen consumption and a major site of oxidative stress due to generation of 
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ROS, where complexes I and III are the main sites of mitochondrial superoxide 
formation (Votyakova and Reynolds 2001).  There is increasing evidence that 
hypertension is associated with an increased mitochondria-derived production of 
ROS in various animal models (Doughan, Harrison et al. 2008; Dikalova, 
Bikineyeva et al. 2010).  In mice, acute (24 h) and chronic (14 day) Ang II 
infusion led to a decreased cardiac expression of mitochondrial electron transport 
chain and Krebs cycle genes (Larkin, Frank et al. 2004), supporting previous 
observations that indicated a role for Ang II and Ang II-induced ROS in the 
depression of mitochondrial energy metabolism (Sanbe, Tanonaka et al. 1995; 
Casademont and Miro 2002; Sorescu and Griendling 2002).  In rat endothelial 
cells, Ang II-induced mtROS generation activates redox-sensitive nuclear factor 
kappa-light-chain-enhancer of activated B cells (NF-κB), which is followed by a 
stimulation of vascular cell adhesion molecule-1 expression, a cytokine involved 
in atherosclerosis lesion formation (Pueyo, Gonzalez et al. 2000).  Recent data 
suggest that brain activation of the RAS elicits intraneuronal signaling, which 
involves an increased production of mitochondrial O2·− (Case, Li et al. 2013), 
modulating ion channel activity and increasing neuronal firing (Yin, Yang et al. 
2010).  Furthermore, overexpression of mitochondrial superoxide dismutase in 
the brain effectively abolishes the central angiotensin II-induced pressor 
response and decreases blood pressure in rodent models of hypertension 
(Zimmerman, Lazartigues et al. 2002; Chan, Wu et al. 2009). It is clear then, that 
Ang II binding to its AT1 receptor has profound effects on the mitochondria and 
metabolism, and therefore this pathway should be considered a potential target 
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in the treatment and/or prevention of hypertension.  The RAS-mitochondria 
connection is strongly supported by work presented in this dissertation, 
demonstrating an inverse relationship between renal AT1r expression and 
components of OXPHOS, despite the continual reduction of the founder SHR 
female nuclear genome (Figure 6.1).  
 
Mitochondrial membranes, proteins, and mitochondrial DNA are particularly 
sensitive to oxidative damage (Yakes and Van Houten 1997; Ballinger, Patterson 
et al. 2000).  ROS has been shown to posttranslationally modify mitochondrial 
proteins leading to their inactivation, as in the case of SOD2 and aconitase, or 
alter their function as occurs with cytochrome c (Brookes, Zhang et al. 2001; 
MacMillan-Crow, Cruthirds et al. 2001; Chen, Deterding et al. 2002). 
Mitochondrial ETC dysfunction has been shown to be causally related to 
oxidative stress during hypertension.  Chan et al. (2009) reported that 
mitochondrial ROS production in the RVLM is elevated in SHRs, and that ROS-
dependent inhibition of mitochondrial ETC complexes I, II and III resulted in a 
feed-forward production of ROS, as well as defects in anti-oxidant production.  
Ballinger et al. (2000) demonstrated that the reactive oxygen species H2O2 and 
peroxynitrite decreased mtRNA expression, mitochondrial protein synthesis and 
decreased cellular ATP levels.  It is possible that ROS, known to be involved with 
the development of hypertension and mitochondrial dysfunction in SHRs, may 
play a role in the development of hypertension in BN/SHR-mtSHR (Figure 6.1).  
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Doughan et al. (2008) has shown that the molecular mechanisms involved in Ang 
II-mediated mitochondrial dysfunction (mitochondrial H2O2 production, and 
decreased mitochondrial glutathione, ADP-stimulated respiration, and decreased 
membrane potential) include protein kinase C (PKC) activation.  Interestingly, 
and of significant importance here, AT1r and α-adrenergic receptors increase 
PKC activity (Tsuchida, Liu et al. 1994; Hein and Kobilka 1995; Karim, 
Defontaine et al. 1995).  Ang II binding to its type 1 receptor causes the G-protein 
mediated stimulation of phospholipase C and phophoinositide 3 kinase, which in 
turn activates PKC.  This pathway is involved with several mechanisms 
associated with the pathogenesis of hypertension, including vasoconstriction, 
catecholamine release, increased renal sodium reabsorption, as well as 
increased vasopressin release and salt appetite (de Gasparo, Catt et al. 2000).  
Buchholz et al. (1991) demonstrated that inhibition of PKC lowers blood pressure 
in SHRs.  Pfaff and Vallon (2002) demonstrated that the renoprotective effect of 
ACE inhibitors in diabetic rats is mediated by the inhibition of PKC-β.  Identifying 
the exact isozyme involved in hypertension may prove to be difficult.  There are 
eight known homologous PKC isozymes, which are products of seven related 
genes (Mochly-Rosen, Das et al. 2012).  Nowak (2002) demonstrated that 
mitochondrial dysfunction and reduced OXPHOS in renal proximal tubular cells is 
mediated by PKC-α and ERK1/2.  Recently, Coble et al. (2014) demonstrated a 
role for central PKC-α in fluid balance by showing the role of PKC-α signaling in 
the SFO in fluid intake stimulated by Ang II in the brain.   To date, several other 
isoforms have been implicated in cardiovascular pathologies, such as diabetes 
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(Geraldes and King 2010), heart failure (Inagaki, Churchill et al. 2006) and stroke 
(Bright and Mochly-Rosen 2005).  Does PKC alter PGC-1α, thereby initiating the 
cascade reducing mitochondrial gene expression and OXPHOS?  Does PKC 
directly, or through a second messenger, alter mitochondrial function in other 
ways?  One future goal will be to elucidate what role, if any, PKC isozymes play 
in mitochondrial dysfunction mediated by Ang II. 
 
I believe that data presented in this dissertation strongly supports a relationship 
between decreased mitochondrial gene expression, mitochondrial function and 
hypertension, and that this altered mitochondrial dynamics may be mediated, at 
least in part, by Ang II binding to its AT1r.  Another mechanism that may underlie 
reduced mt-gene expression is altered activity of the sympathetic nervous 
system. Elevated RSNA plays an important role in the development and 
maintenance of hypertension in the SHR (Judy, Watanabe et al. 1976; Karim, 
Defontaine et al. 1995).   Increases in RSNA decrease urinary sodium and water 
excretion by increasing renal tubular water and sodium reabsorption throughout 
the nephron, decrease renal blood flow and glomerular filtration rate by 
constricting the renal vasculature, and increase activity of the renin-angiotensin 
system by stimulating renin release from juxtaglomerular granular cells (DiBona 
and Kopp 1997; Osborn, Plato et al. 1997; DiBona 2000).  Activation, or 
overactivation of adrenergic receptors may trigger downstream effects, 
potentially altering expression of PGC-1α through, for instance phosphorylation 
AMP kinase (AMPK)(Fan, Rhee et al. 2004), cAMP response element-binding 
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protein (CREB (Fernandez-Marcos and Auwerx 2011) or others (García-
Giménez, Gimeno et al. 2011) to ultimately decrease mt-gene expression.  
Adrenergic activation also increases PKC activity, which has been shown to 
mediate mitochondrial dysfunction in conjunction with ERK1/2 (Nowak 2002).   A 
second future goal is to evaluate the relationship between the sympathetic 
nervous system and mitochondrial function, as elevated RSNA is a key 
component of most forms of hypertension, including primary hypertension in 
humans.  Evaluating RAS with RSNA could provide valuable information on how 
each contribute to hypertension individually and in concert with one another.  
 
PGC-1α plays a central role in regulating mitochondrial content and function 
within cells, because of its ability to co-activate and augment several promoters 
of nuclear-encoded mitochondrial genes, as well as regulating mitochondrial 
transcription via the NRF-Tfam pathway (Wu, Puigserver et al. 1999).  PGC-1α 
regulates NRF-dependent transcription, increases expression of both 
mitochondrial and nuclear encoded genes of oxidative phosphorylation and 
induces mitochondrial biogenesis (Scarpulla 2002).  It has been shown that 
metabolic functions are controlled by PGC-1α  in a tissue specific manner in 
brown fat, muscle and liver (Puigserver 2005), however kidney regulation of  
PGC-1α  and its effectors was unknown until now.  Results from our studies 
show a clearly coordinated-reduction of the kidney-specific expression of nuclear 
and mitochondrial genes vital to OXPHOS coinciding with the manifestation of 
hypertension.  As mentioned above, it is likely that this nuclear-mitochondrial 
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gene downregulation is being driven by upstream events.  A third future goal, 
though related to the other two, is to elucidate the exact mechanisms that 
regulate PGC-1α, particularly in a tissue-specific manner.  Understanding these 
mechanisms will be critical in understanding the etiology of hypertension and 
cardiovascular disease.   
 
I have postulated thus far that reduced mitochondrial gene expression and 
OXPHOS may be driving hypertension.  It is possible, however, that elevated 
blood pressure is driving reduced mitochondrial function.  Elevated ROS can 
cause reduced OXPHOS, making the mitochondria less efficient.  The converse 
is true as well, as less efficient OXPHOS can increase mtROS.  Oxidative 
mitochondrial DNA damage may affect the synthesis of components of the 
respiratory chain, which in turn can further increase ROS production, initiating a 
feed-forward cycle (Figure 6.1).  Chronic over activity of renal sympathetic 
nerves, elevated blood pressure and a rightward shift in the renal function curve 
may ultimately drive down the expression of mitochondrial genes.  High 
metabolic activity in young SHRs may drive mitochondrial gene expression down 
in adulthood, coinciding with the chronic elevation of BP.  This “chicken-or-the-
egg” type question is crucial in understanding the pathology of the disease, and 
one that needs to be addressed.  One way this could be accomplished is to trace 
the pathogenesis of the disease in developing SHRs, while monitoring tissue-
specific mitochondrial function. 
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Within this dissertation, I have presented data supporting the hypotheses that the 
location, genetic expression and abundance of AT1 receptors is associated with 
development and maintenance of spontaneous hypertension.  Both renal- and 
hypothalamic-specific expression of AT1 receptors was associated with 
hypertension in rats with decreasing SHR nuclear genome.  Secondly, I 
presented data to support the hypothesis that the maternal inheritance of the 
mitochondrial genome may play a specific role in the development of 
hypertension, though mitochondrial function is most likely altered upstream of the 
well-known nuclear-mitochondrial pathway, and there is significant evidence that 
the RAS is involved.  Most importantly, data presented here indicates both 
intrinsic and extrinsic mechanisms of the kidney, i.e. the RAS, as well as genetic 
and genomic mechanisms of the kidney may be driving that spontaneous 
hypertension.   A major question remains: Why is there tissue-specific regulation 
of mitochondrial gene expression and OXPHOS, and how is this accomplished?  
Future directions will try to elucidate what exact mechanisms are driving 
decreased OXPHOS, as well as further investigate the importance of tissue-
specific regulation of mitochondria, and how this may be causal to the 
manifestation of hypertension. 
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Figure 6.1: Interactions among RAS and AT1r, reduced mitochondrial gene 
expression, reduced OXPHOS in the development of hypertension.  There are 
several possible interactions presented above which ultimately lead to chronic 
elevation of arterial pressure.  
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